Data / Research funding / Pulmonary Fibrosis
Pulmonary Fibrosis: 473 NIH awards ($3.5B) to 146 organizations
473 NIH awards ($3.5B) in the NIH spending category Pulmonary Fibrosis, to 146 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
473 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| NIEHS - Lung Microbiome Promotes Emphysema by Activating Lung Innate Immunity | NIH | National Cancer Institute | 2021 to 2025 | $2,960,824,321 | August 31, 2025 | August 30, 2026 | BRISCOE, LYNN | reporter.nih.gov |
| 1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $9,400,136 | September 1, 2020 | June 25, 2024 | MARTINEZ, FERNANDO J | reporter.nih.gov |
| Mechanisms Regulating Lung Injury and Early Lung Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $7,661,704 | July 1, 2023 | June 30, 2028 | SCHWARTZ, DAVID ALBERT | reporter.nih.gov |
| Precision phenotyping of emphysema in the elderly: the MESA Lung Study | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $6,794,185 | August 2, 2004 | January 31, 2027 | BARR, R GRAHAM | reporter.nih.gov |
| Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $6,050,572 | September 20, 2019 | March 31, 2027 | SPINO, CATHERINE A | reporter.nih.gov |
| Clinical Genetics and Screening for Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $5,442,199 | January 1, 2016 | November 30, 2026 | HUNNINGHAKE, GARY MATTHEW | reporter.nih.gov |
| Program to promote lung regeneration and block fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $4,819,926 | February 15, 2020 | February 14, 2026 | CHAPMAN, HAROLD A | reporter.nih.gov |
| Novel Functions of Lung Macrophages and Fibroblasts in Pulmonary Inflammation and Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $4,646,035 | March 25, 2019 | February 28, 2026 | PETERS-GOLDEN, MARC L | reporter.nih.gov |
| High performance wearable body odor sensor arrays for disease detection and monitoring | NIH | National Center for Advancing Translational Sciences | 2022 to 2025 | $4,350,648 | August 10, 2022 | May 31, 2027 | FAN, XUDONG | reporter.nih.gov |
| Preclinical Pulmonary Fibrosis, an opportune rare disease cohort | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $4,290,758 | August 20, 2020 | July 31, 2026 | SCHWARTZ, DAVID ALBERT | reporter.nih.gov |
| Molecular Regulation of Progressive Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $4,220,741 | March 1, 2020 | February 28, 2027 | NOBLE, PAUL WESLEY | reporter.nih.gov |
| PET-MR Imaging of pulmonary fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $4,079,636 | July 1, 2021 | June 30, 2026 | CARAVAN, PETER D | reporter.nih.gov |
| Cell competition in pulmonary fibrosis and ARDS | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,796,920 | August 20, 2022 | July 31, 2029 | DE LANGHE, STIJN PIET JOHAN | reporter.nih.gov |
| Spatiotemporal genomic regulation of disease initiation and progression in pulmonary fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,775,343 | January 1, 2019 | April 30, 2028 | BANOVICH, NICHOLAS ELI | reporter.nih.gov |
| Molecular Imaging CCR2 Lung Inflammation and Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,741,003 | February 5, 2021 | December 31, 2026 | BRODY, STEVEN | reporter.nih.gov |
| Phase 1 study of oral epigallocatechin-3-gallate (EGCG) in IPF patients | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $3,521,973 | August 31, 2024 | April 30, 2027 | MARTINEZ, FERNANDO J | reporter.nih.gov |
| An Aging Alveolar Lung Model in Microgravity | NIH | National Center for Advancing Translational Sciences | 2025 | $3,504,482 | September 30, 2025 | August 31, 2028 | ZHANG, Y. SHRIKE | reporter.nih.gov |
| Mechanisms of Alveolar Homeostasis, Injury, Regeneration, and Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,471,063 | March 1, 2022 | February 28, 2029 | ZEMANS, RACHEL LYNNE | reporter.nih.gov |
| Immunobiology of Lung Injury and Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $3,455,443 | January 21, 2019 | December 31, 2024 | MOORE, BETHANY B. | reporter.nih.gov |
| Metal Exposure and Subclinical Lung Disease in Adult E-cigarette Users | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,409,256 | February 15, 2021 | January 31, 2027 | OELSNER, ELIZABETH | reporter.nih.gov |
| In vivo endobronchial OCT for IPF diagnosis and therapy response assessment | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $3,179,658 | June 1, 2020 | May 31, 2026 | HARIRI, LIDA P | reporter.nih.gov |
| Targeted Gene Delivery Systems Treating Lung Diseases | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,172,072 | June 15, 2022 | May 31, 2026 | TIRRELL, MATTHEW | reporter.nih.gov |
| Genetic and Genomic Characterization of the Occurrence and Progression of Interstitial Lung Abnormalities | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $3,032,111 | August 1, 2017 | November 30, 2027 | HUNNINGHAKE, GARY MATTHEW | reporter.nih.gov |
| Genomic Analysis of Tissue and Cellular Heterogeneity in IPF | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,021,766 | August 14, 2015 | June 30, 2026 | KAMINSKI, NAFTALI | reporter.nih.gov |
| Development of a Novel Hyaluronan Inhibitor for the Treatment of Group 3 Pulmonary Hypertension (PH) | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $2,993,376 | May 15, 2024 | April 30, 2027 | PALADINI, RUDY | reporter.nih.gov |
| Lung Remodeling Mediated by Telomere Dysfunction in Alveolar Type II Cells | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,974,783 | July 5, 2018 | January 31, 2027 | WOLTERS, PAUL J | reporter.nih.gov |
| Surfactant Protein C Mouse Models: A Fit For Purpose Preclinical Platform For Advancing Discovery In And Treatment Of Idiopathic Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,974,500 | January 1, 2021 | December 31, 2025 | BEERS, MICHAEL FRANCIS | reporter.nih.gov |
| Integrated analysis of multi-omic QTLs at single cell resolution | NIH | National Human Genome Research Institute | 2022 to 2025 | $2,938,710 | September 15, 2022 | June 30, 2026 | BANOVICH, NICHOLAS ELI | reporter.nih.gov |
| Rheumatoid Arthritis-associated Parenchymal Lung Disease: Clinical and Molecular Phenotypes | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,937,551 | April 15, 2022 | March 31, 2027 | WASHKO, GEORGE R | reporter.nih.gov |
| Epithelial-Mesenchymal Interactions in Fibrosis Resolution | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,901,344 | August 6, 2009 | April 30, 2027 | TSCHUMPERLIN, DANIEL J. | reporter.nih.gov |
| Beyond the Barrier: Alveolar Epithelial Cell Biology in Health and Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,844,000 | August 15, 2021 | June 30, 2025 | BOROK, ZEA | reporter.nih.gov |
| Pulmonary Fibrosis and Telomerase Dysfunction | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,838,035 | July 1, 2009 | June 30, 2025 | GARCIA, CHRISTINE KIM | reporter.nih.gov |
| Noradrenergic mechanisms of IPF | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,831,007 | March 5, 2022 | June 30, 2026 | HERZOG, ERICA L | reporter.nih.gov |
| Molecular Determinants of Usual Interstitial Pneumonia (UIP) | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,826,957 | April 1, 2022 | March 31, 2027 | SCHWARTZ, DAVID ALBERT | reporter.nih.gov |
| S-glutathionylation chemistry in fibrotic lung remodeling | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,783,548 | January 1, 2017 | December 31, 2023 | JANSSEN-HEININGER, YVONNE M. W. | reporter.nih.gov |
| Targeting vascular dysfunction to promote lung repair and fibrosis resolution | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,782,716 | March 5, 2022 | February 28, 2027 | LIGRESTI, GIOVANNI | reporter.nih.gov |
| Sineoculis Homeobox Homolog 1 (Six1) in Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,769,865 | April 1, 2021 | March 31, 2027 | KARMOUTY-QUINTANA, HARRY | reporter.nih.gov |
| Using MRI To Visualize Regional Therapy Response In Idiopathic Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,741,962 | May 6, 2015 | March 31, 2026 | DRIEHUYS, BASTIAAN | reporter.nih.gov |
| Lung Functional Avoidance Radiotherapy Using Hyperpolarized Xenon MRI | NIH | National Cancer Institute | 2021 to 2025 | $2,741,941 | September 17, 2021 | August 31, 2027 | RUSET, IULIAN CONSTANTIN | reporter.nih.gov |
| Signaling mechanisms and functions related to patho-physiology of vascular, lung and blood systems | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,736,942 | February 1, 2017 | June 30, 2024 | WU, DIANQING | reporter.nih.gov |
| Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $2,694,152 | September 16, 2013 | July 31, 2025 | THANNICKAL, VICTOR J. | reporter.nih.gov |
| A Novel Bispecific Antibody for the Treatment of Idiopathic Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,662,971 | April 1, 2022 | March 31, 2027 | FANGER, NEIL A | reporter.nih.gov |
| Alveolar Epithelial Cell Dysfunction in Pulmonary Fibrosis: Leveraging SFTPC Mutations for Discovery of Molecular and Cellular Targets | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,642,855 | July 15, 2019 | June 30, 2028 | BEERS, MICHAEL FRANCIS | reporter.nih.gov |
| Novel compounds for the treatment of systemic sclerosis-associated interstitial lung disease | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $2,600,290 | July 15, 2024 | June 30, 2027 | SCARNEO, SCOTT | reporter.nih.gov |
| Mechanisms of lung macrophage programming by MUC5B during health and disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,591,393 | August 1, 2016 | April 30, 2027 | EVANS, CHRISTOPHER M | reporter.nih.gov |
| Using Multi-Omics to Define Regulators and Drivers of Granulomatous Inflammation and Chronic Beryllium Disease | NIH | National Institute of Environmental Health Sciences | 2022 to 2025 | $2,590,938 | February 9, 2022 | November 30, 2026 | MAIER, LISA A | reporter.nih.gov |
| Role of lactate transporters in pulmonary fibrosis | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,570,068 | June 5, 2023 | May 31, 2028 | OLDHAM, WILLIAM MICHAEL | reporter.nih.gov |
| AMPK in the Development and resolution of Lung Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,567,547 | January 15, 2019 | June 30, 2028 | ZMIJEWSKI, JAROSLAW WALDEMAR | reporter.nih.gov |
| Modeling, pathogenesis and treatment of idiopathic pulmonary fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $2,527,128 | September 20, 2016 | May 31, 2025 | SNOECK, HANS-WILLEM E | reporter.nih.gov |
| Genetic and Immuno-inflammatory Drivers of Post-acute Pulmonary Sequelae of SARS-CoV-2 | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,526,022 | February 5, 2023 | January 31, 2028 | ABRAMSON, STEVEN B | reporter.nih.gov |
| Developing a patient-specific organoid model of pulmonary fibrosis using iPSCs | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,476,283 | December 15, 2020 | November 30, 2025 | KOTTON, DARRELL N. | reporter.nih.gov |
| Alveolar epithelial stress-induced polyploidization in lung injury and repair | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,458,344 | May 15, 2022 | April 30, 2027 | GOTTARDI, CARA J | reporter.nih.gov |
| Oxidized Phospholipids Derived from Apoptotic Pneumocytes Drives Macrophage Activation and Initiates Lung Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,455,688 | September 1, 2021 | May 31, 2026 | KIM, KEVIN KEEWOUN | reporter.nih.gov |
| Metabolic reprogramming of Alveolar Type 2 cells in response to lung injury | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,446,943 | July 1, 2022 | September 30, 2026 | GUTTENTAG, SUSAN H. | reporter.nih.gov |
| Targeting Fibroblast Discoidin Domain Receptor 2 for Immunotherapy to Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,423,194 | December 1, 2021 | February 28, 2026 | KIM, KEVIN KEEWOUN | reporter.nih.gov |
| Learning Precision Medicine for Rare Diseases Empowered by Knowledge-driven Data Mining | NIH | National Human Genome Research Institute | 2023 to 2025 | $2,419,821 | September 6, 2023 | June 30, 2027 | LIU, HONGFANG | reporter.nih.gov |
| Basal cells in airway and alveolar remodeling | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,407,737 | May 1, 2022 | April 30, 2026 | STRIPP, BARRY R | reporter.nih.gov |
| Trial of Pirfenidone to Prevent Progression of Chronic Kidney Disease (TOP-CKD) | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $2,400,751 | September 13, 2018 | August 31, 2025 | IX, JOACHIM H | reporter.nih.gov |
| Lung fibrosis modeling and compound testing platform using fibrotic lung ECM that recreates the fibrotic disease environment to improve predictiveness and accelerate anti-fibrotic drug development | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,389,178 | September 1, 2021 | February 28, 2024 | O'NEILL, JOHN DAVID | reporter.nih.gov |
| Epithelial stem/progenitor cells as repair agents in diffuse alveolar damage | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $2,388,592 | September 21, 2016 | May 31, 2025 | CHAPMAN, HAROLD A | reporter.nih.gov |
| Conformational regulation of TGF-β activation by integrin αvβ6 | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,383,385 | July 1, 2023 | June 30, 2027 | NISHIMURA, STEPHEN L | reporter.nih.gov |
| Regulation and manipulation of the telomerase RNA component in hematopoiesis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,367,468 | December 1, 2015 | May 14, 2026 | AGARWAL, SUNEET | reporter.nih.gov |
| Validation of an in vitro model of progressive fibrosis that mimics Idiopathic Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,367,083 | February 15, 2021 | January 31, 2026 | GOMPERTS, BRIGITTE N | reporter.nih.gov |
| Therapeutic ECM Resorption in Cellular Systems and Precision Cut Lung Slices. | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,360,154 | December 15, 2020 | November 30, 2025 | TSCHUMPERLIN, DANIEL J. | reporter.nih.gov |
| Metabolic Landscape of the Aging Lung | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,355,987 | May 15, 2020 | April 30, 2026 | BARNES, JARROD W. | reporter.nih.gov |
| Host cellular network governing the development of post SARS-CoV-2 tissue sequelae | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,351,771 | February 14, 2020 | May 31, 2030 | SUN, JIE | reporter.nih.gov |
| Mesenchymal modulation of epithelial metaplasia in lung fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,340,812 | February 1, 2021 | December 31, 2024 | PENG, TIEN | reporter.nih.gov |
| Mechanistic studies of the genetic contribution of desmoplakin to pulmonary fibrosis in alveolar type 2 cells | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,340,458 | August 15, 2023 | July 31, 2027 | WILSON, ANDREW A | reporter.nih.gov |
| Uncovering the genetically-driven differential susceptibility to chronic obstructive pulmonary disease and pulmonary fibrosis | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,300,073 | December 15, 2022 | November 30, 2027 | CHO, MICHAEL H. | reporter.nih.gov |
| Targeting durotaxis in lung injury and fibrosis | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,293,539 | December 1, 2021 | November 30, 2026 | MEDOFF, BENJAMIN DAVID | reporter.nih.gov |
| Regulation of lipid metabolism in pulmonary Type 2 cells | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,257,994 | December 20, 2021 | November 30, 2026 | GARCIA-ARCOS, ITSASO | reporter.nih.gov |
| Mechanisms of Telomere-Mediated Lung Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,251,236 | July 10, 2018 | June 30, 2028 | ALDER, JONATHAN K. | reporter.nih.gov |
| Program on cellular metabolism and lung fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,227,500 | January 3, 2017 | December 31, 2025 | LIU, GANG | reporter.nih.gov |
| Role of Chaperone GRP78 and Mitochondrial Dysfunction in ER Stress-Mediated Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,221,038 | August 1, 2013 | December 31, 2026 | ZHOU, BEIYUN | reporter.nih.gov |
| Cadmium-potentiated metabolic reprogramming in pathogenesis of lung fibrosis | NIH | National Institute of Environmental Health Sciences | 2021 to 2025 | $2,220,674 | August 1, 2021 | May 31, 2027 | GO KANG, YOUNG-MI | reporter.nih.gov |
| Deciphering the role of p16INK4A+ fibroblasts in lung fibrosis | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,216,263 | February 1, 2022 | November 30, 2025 | PENG, TIEN | reporter.nih.gov |
| Lung transplant injury drives chronic lung allograft dysfunction via recruitment ofmonocyte-derived alveolar macrophages | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,211,115 | September 1, 2020 | August 31, 2024 | MISHARIN, ALEXANDER | reporter.nih.gov |
| Dysregulated Immunometabolism and Premature Senescence in Corticosteroid-Refractory Severe Asthma | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,209,066 | February 1, 2023 | January 31, 2030 | RAY, ANURADHA | reporter.nih.gov |
| Loss of Endothelial S1PR1 Drives Post-Influenza Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,206,371 | June 15, 2023 | May 31, 2028 | KNIPE, RACHEL S | reporter.nih.gov |
| Immunologic and Clinical Sequelae after COVID-19 in Patients with Systemic Autoimmune Rheumatic Diseases | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 to 2025 | $2,205,056 | February 1, 2023 | January 31, 2028 | SPARKS, JEFFREY ANDREW | reporter.nih.gov |
| Phase 1 study of oral epigallocatechin-3-gallate (EGCG) in IPF patients | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $2,201,114 | May 20, 2022 | June 25, 2024 | MARTINEZ, FERNANDO J | reporter.nih.gov |
| 1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $2,196,466 | August 31, 2024 | March 31, 2026 | MARTINEZ, FERNANDO J | reporter.nih.gov |
| Mechanisms of epithelial repair and remodeling in pulmonary fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,193,295 | July 15, 2020 | June 30, 2025 | KROPSKI, JONATHAN ANDREW | reporter.nih.gov |
| The Impaired FRNK in IPF | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,190,760 | June 1, 2021 | May 31, 2026 | DING, QIANG | reporter.nih.gov |
| Therapeutic targeting of MUC5B in a novel ferret model of idiopathic pulmonary fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,189,214 | December 15, 2020 | November 30, 2025 | ROWE, STEVEN MARK | reporter.nih.gov |
| Validating Quantitative Magnetic Resonance Imaging Biomarkers of Idiopathic Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,183,031 | January 1, 2019 | December 31, 2024 | CLEVELAND, ZACKARY I | reporter.nih.gov |
| Modeling to Design Treatments for Idiopathic Lung Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,181,892 | July 1, 2021 | June 30, 2026 | PEIRCE-COTTLER, SHAYN | reporter.nih.gov |
| Genes and Transcripts that Interact with MUC5B in Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,180,989 | June 1, 2020 | May 31, 2025 | SCHWARTZ, DAVID ALBERT | reporter.nih.gov |
| ZIP8-dependent Zinc Metabolic Regulation in Alveolar Progenitor Cell Aging and Fibrosis | NIH | National Institute on Aging | 2022 to 2025 | $2,167,288 | August 1, 2022 | April 30, 2027 | LIANG, CAROL JIURONG | reporter.nih.gov |
| The Thromboxane-Prostanoid Receptor in Radiation-Induced Pulmonary Fibrosis | NIH | National Cancer Institute | 2023 to 2025 | $2,141,378 | August 22, 2023 | July 31, 2028 | WEST, JAMES D | reporter.nih.gov |
| The Role of Telomeres in Lung Transplant Recipient Immunity and Outcomes | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,129,020 | March 5, 2023 | February 29, 2028 | MCDYER, JOHN F | reporter.nih.gov |
| Heterogeneity and Regulation of the DNA Methylome in IPF Mesenchymal Cells | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,110,523 | February 1, 2023 | November 30, 2026 | HUANG, STEVEN K | reporter.nih.gov |
| Cellular crosstalk and molecular mechanisms in the initiation and progression of pulmonary fibrosis | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,110,277 | June 15, 2022 | May 31, 2026 | TATA, PURUSHOTHAMA RAO | reporter.nih.gov |
| Mitigation of Radiation Injury via Vascular Regeneration and Remodeling | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,104,000 | June 5, 2020 | May 31, 2025 | CHUTE, JOHN P | reporter.nih.gov |
| A Novel PAI-1 Function Drives Lung Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,098,445 | December 15, 2022 | November 30, 2026 | SISSON, THOMAS H | reporter.nih.gov |
| Proteomic Profiling of Idiopathic Pulmonary Fibrosis Progression Trajectory | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,082,531 | September 1, 2023 | May 31, 2028 | OLDHAM, JUSTIN M | reporter.nih.gov |
| Mitochondrial DNA Injury is a Key Contributor to the Development of Chemical Lung Injury | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,073,978 | August 1, 1987 | February 28, 2027 | MATALON, SADIS | reporter.nih.gov |
| Fibroblast heterogeneity in pulmonary fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,049,497 | April 1, 2020 | March 31, 2025 | SHEPPARD, DEAN | reporter.nih.gov |
| Advanced Pre-clinical development of Nox4 inhibitors for Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $2,045,720 | June 1, 2024 | May 31, 2027 | PATTI, JOSEPH | reporter.nih.gov |
| Hybrid Hydrogel Biomaterials Comprising Clickable Decellularized Extracellular Matrix for Engineering Dynamic 3D Models of Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,041,592 | August 1, 2020 | July 31, 2025 | MAGIN, CHELSEA M | reporter.nih.gov |
| The Role of KCNMB1 and the Large Conductance Potassium (BK) Channel in Myofibroblast Differentiation and Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,030,850 | April 1, 2015 | May 31, 2026 | HUANG, STEVEN K | reporter.nih.gov |
| Role of the ER stress transcription factor XBP1S in the development of idiopathic pulmonary fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $2,025,159 | December 15, 2020 | November 30, 2025 | CHEN, GANG | reporter.nih.gov |
| eNamptorTM: A Humanized mAb To Reduce the Severity of Radiation Pneumonitis and Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $2,000,000 | June 1, 2020 | May 31, 2023 | GARCIA, JOE G. N. | reporter.nih.gov |
| PET imaging of radiation induced lung injury | NIH | National Cancer Institute | 2022 to 2023 | $1,996,724 | May 4, 2020 | May 31, 2025 | HUMBLET, VALERIE | reporter.nih.gov |
| Pathogenesis of Cardiopulmonary Fibrosis Associated with Heart Failure in the Elderly | NIH | National Institute on Aging | 2021 to 2023 | $1,989,048 | January 1, 2020 | January 31, 2024 | PENUMATSA, KRISHNA C | reporter.nih.gov |
| Sox9 Regulation of Fibroblast Activation and Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $1,951,862 | August 15, 2021 | May 31, 2026 | MADALA, SATISH K | reporter.nih.gov |
| Microbiota Regulation of Pulmonary Complications Post-HCT | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $1,941,600 | September 20, 2021 | August 31, 2026 | ZHOU, XIAOFENG | reporter.nih.gov |
| Gut Microbiota and Host Regulatory Cross-Talk in Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $1,936,226 | August 15, 2022 | July 31, 2026 | O'DWYER, DAVID NOEL | reporter.nih.gov |
| Collagen Oxidation, Myofibroblast Activation and Age-Associated Pulmonary Fibrosis | NIH | National Institute on Aging | 2022 to 2025 | $1,921,934 | September 1, 2022 | June 30, 2027 | JANSSEN-HEININGER, YVONNE M. W. | reporter.nih.gov |
| Mechanisms Controlling Expansion and Lineage Specification of Airway Progenitors in Development and Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,919,136 | January 1, 2017 | June 30, 2023 | CARDOSO, WELLINGTON V. | reporter.nih.gov |
| Novel Mechanisms of Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,871,520 | May 20, 2023 | April 30, 2027 | MCCORMACK, FRANCIS XAVIER | reporter.nih.gov |
| Unraveling the molecular origins of chronic parenchymal lung diseases | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,861,890 | September 1, 2024 | August 31, 2029 | KROPSKI, JONATHAN ANDREW | reporter.nih.gov |
| CMKLR1-Targeted Molecular Imaging of Inflammation as a Precision Medicine Tool in Acute Lung Injury and Fibrotic Lung Diseases | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,859,720 | September 1, 2023 | July 31, 2028 | TAVAKOLI, SINA | reporter.nih.gov |
| ECM Proteomics in lung fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,850,296 | December 15, 2019 | November 30, 2023 | EICKELBERG, OLIVER | reporter.nih.gov |
| Speckle x-ray imaging: detecting early changes in lung microstructure | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,847,778 | February 1, 2023 | November 30, 2026 | NOEL, PETER B | reporter.nih.gov |
| Defining the molecular and radiologic phenotype of progressive RA-ILD | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,845,758 | August 1, 2023 | May 31, 2028 | LEE, JOYCE SUJIN | reporter.nih.gov |
| Macrophage driven, profibrotic adrenergic nerve remodeling in SSc-ILD | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,822,959 | April 5, 2020 | March 31, 2026 | HERZOG, ERICA L | reporter.nih.gov |
| Development, Formulation and Inhalational Delivery of a New Peptide for ILD | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $1,796,712 | December 15, 2020 | November 30, 2025 | SHETTY, SREERAMA | reporter.nih.gov |
| Fibrogenic activation and memory in the lung mesenchyme | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,776,199 | December 1, 2022 | November 30, 2026 | TSCHUMPERLIN, DANIEL J. | reporter.nih.gov |
| Mechano-niche in Lung Repair after Injury | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,770,302 | June 15, 2021 | December 31, 2023 | ZHOU, YONG | reporter.nih.gov |
| Targeting CHI3L1 and its receptors in Hermansky-Pudlak Syndrome-associated lung disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $1,769,742 | March 20, 2020 | February 28, 2026 | ZHOU, YANG | reporter.nih.gov |
| Role of Surfactant Protein-C Mutation and Ozone Exposure in the Exacerbation of Pulmonary Fibrosis | NIH | National Institute of Environmental Health Sciences | 2021 to 2025 | $1,711,701 | February 1, 2021 | August 31, 2025 | VENOSA, ALESSANDRO | reporter.nih.gov |
| Completion of IND-enabling studies required for first-in-human studies of a novel oral therapeutic agent for treating pulmonary fibrosis | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $1,709,661 | March 5, 2022 | February 29, 2024 | HARTMAN, JAMES CRAIG | reporter.nih.gov |
| Role of Epac1 in the Pathogenesis of Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $1,690,000 | April 1, 2022 | March 31, 2027 | HADRI, LAHOUARIA | reporter.nih.gov |
| Interstitial Lung Abnormalities: Defining the Phenotype, Causes, and Consequences. | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,686,795 | July 1, 2013 | April 30, 2025 | HUNNINGHAKE, GARY MATTHEW | reporter.nih.gov |
| Traffic-related air pollution exacerbates AD-relevant phenotypes in a genetically susceptible rat model via neuroinflammatory mechanism(s) | NIH | National Institute on Aging | 2024 to 2025 | $1,681,101 | May 1, 2021 | April 30, 2027 | LEIN, PAMELA J | reporter.nih.gov |
| Survival prediction in patients with progressive fibrosing interstitial lung disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $1,680,000 | June 15, 2022 | May 31, 2027 | YOSHIDA, HIROYUKI | reporter.nih.gov |
| Epithelial Protective Effects of Thyroid Hormone Signaling in Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,667,970 | December 15, 2018 | November 30, 2024 | KAMINSKI, NAFTALI | reporter.nih.gov |
| Post-Transcriptional Regulation of Lung Fibrosis. | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,660,310 | September 5, 2023 | May 31, 2028 | CHE, PULIN | reporter.nih.gov |
| Microscopic EB-OCT imaging to predict progression in interstitial lung abnormalities | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,659,016 | June 1, 2024 | May 31, 2029 | HARIRI, LIDA P | reporter.nih.gov |
| Development and Validation of a Prognostic Transcriptomic Signature for Chronic Hypersensitivity Pneumonitis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,650,060 | August 1, 2020 | July 31, 2025 | FERNANDEZ, EVANS | reporter.nih.gov |
| Reducing Fibroblast Persistence in Pulmonary Fibrosis as a Mechanism of Resolution | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,624,935 | August 1, 2019 | July 31, 2025 | REDENTE, ELIZABETH FRANCES | reporter.nih.gov |
| Metabolic Regulation of Myofibroblast Differentiation | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $1,620,000 | April 1, 2020 | March 31, 2026 | HAMANAKA, ROBERT BRIAN | reporter.nih.gov |
| Cell-cell and cell-matrix interactions driving progressive fibrosis in interstitial lung diseases | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,617,251 | September 1, 2024 | August 31, 2029 | GOMPERTS, BRIGITTE N | reporter.nih.gov |
| Designing supramolecular delivery strategies to understand and exploit synergies in immunoregenerative medicine | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $1,615,000 | August 1, 2022 | June 30, 2027 | RODELL, CHRISTOPHER B | reporter.nih.gov |
| Profibrotic Mechanisms of the TRPV4-PI3K-gamma Protein Complex | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $1,610,000 | August 1, 2021 | December 31, 2025 | OLMAN, MITCHELL ALAN | reporter.nih.gov |
| Thromboxane Receptor Signaling in Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,600,701 | December 1, 2019 | November 30, 2024 | KROPSKI, JONATHAN ANDREW | reporter.nih.gov |
| Chitinase1 Regulation of Pulmonary Fibrosis and Therapeutic Targeting | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $1,593,750 | September 15, 2021 | June 30, 2025 | LEE, CHUN GEUN | reporter.nih.gov |
| Localizing Therapeutics to Target Lung Myofibroblasts and Reverse Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,587,996 | September 17, 2024 | June 30, 2028 | OLENYUK, BOGDAN | reporter.nih.gov |
| Repurposing esomeprazole for the treatment of scleroderma | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2025 | $1,579,012 | February 23, 2023 | April 30, 2028 | GHEBRE, YOHANNES T | reporter.nih.gov |
| Targeting WNT7A Signaling in Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,574,532 | August 1, 2024 | July 31, 2028 | JIANG, DIANHUA | reporter.nih.gov |
| Modeling pulmonary fibrosis progression caused by differential mechanical stretch | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $1,569,231 | August 5, 2022 | July 31, 2026 | ZHAO, RUOGANG | reporter.nih.gov |
| Bromodomain-containing Protein 4 in Profibrotic Gene Expression and Lung Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,568,673 | February 1, 2021 | March 3, 2023 | SANDERS, YAN | reporter.nih.gov |
| Delineating the role of let-7 microRNA on lung AT2 cell homeostasis, alveolar regeneration, and interstitial lung disease | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,566,027 | April 1, 2023 | March 31, 2027 | RODRIGUEZ, ANTONY | reporter.nih.gov |
| Induction, fate and function of inflammatory fibroblasts | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,549,342 | July 15, 2024 | June 30, 2028 | SHEPPARD, DEAN | reporter.nih.gov |
| Fibroblast Biology and Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,545,353 | August 15, 2020 | July 31, 2025 | DULIN, NICKOLAI O | reporter.nih.gov |
| A multi-scale computational model of the extracellular matrix of the lung | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,533,586 | June 1, 2018 | May 31, 2024 | SUKI, BELA | reporter.nih.gov |
| The Role of Iron In Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,527,545 | December 1, 2022 | November 30, 2026 | LIU, LIN | reporter.nih.gov |
| Selective Inhibitors of T Cell Activation Target Exportin-1 at Cys528 to Suppress Pathological T Cell Activation | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,526,530 | January 23, 2023 | December 31, 2027 | ADAMS, DREW JAMES | reporter.nih.gov |
| Role of ADAM17 in MDSC-Mediated Development of Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $1,525,000 | April 5, 2020 | March 31, 2026 | BRYANT, ANDREW JUSTIN | reporter.nih.gov |
| The pathophysiology of vascular remodeling in pulmonary hypertension | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,524,759 | September 6, 2024 | June 30, 2028 | PI, XINCHUN | reporter.nih.gov |
| Molecular regulation of BMPRII stability in lung fibrosis | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,514,000 | September 1, 2023 | May 31, 2027 | ZHAO, YUTONG | reporter.nih.gov |
| The pivotal role of macrophages in regulating pulmonary fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,508,766 | April 1, 2019 | March 31, 2025 | BALLINGER, MEGAN N | reporter.nih.gov |
| Mitochondrial DNA and Sex Differences in Scleroderma-Associated ILD | NIH | National Heart, Lung, and Blood Institute | 2025 | $1,498,380 | September 23, 2025 | August 31, 2027 | HERZOG, ERICA L | reporter.nih.gov |
| The role of quantitative CT and radiomic biomarkers for precision medicine in pulmonary fibrosis | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,493,792 | February 5, 2024 | January 31, 2029 | NOTH, IMRE | reporter.nih.gov |
| Cross-Disease Multi-Modality Mapping of the Human Lung | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,491,262 | September 1, 2024 | August 31, 2029 | SUN, XIN | reporter.nih.gov |
| Prognostic Biomarker Development in Progressive Fibrosing Interstitial Lung Disease | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,481,799 | January 1, 2024 | December 31, 2028 | OLDHAM, JUSTIN M | reporter.nih.gov |
| Analysis of immunologic mechanisms in patients with chronic lung disease after acute COVID infection | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,479,938 | August 15, 2024 | May 31, 2028 | TWIGG, HOMER L | reporter.nih.gov |
| Translating a Novel Therapeutic Approach to the Treatment for Idiopathic Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,463,750 | September 15, 2024 | July 31, 2027 | HU, PING | reporter.nih.gov |
| Type II Alveolar Redox Control in Fibrogenesis and Resolution | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,462,242 | December 1, 2020 | November 30, 2024 | MORA, ANA LUCIA | reporter.nih.gov |
| Molecular and morphometric imaging of coagulation and inflammation in pulmonary embolism pathogenesis | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,451,843 | September 15, 2024 | June 30, 2029 | KESSINGER, CHASE WILLIAM | reporter.nih.gov |
| Regulation of distal basal cells in terminal and respiratory airway regeneration | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,427,217 | August 15, 2024 | July 31, 2029 | KADUR LAKSHMINARASIM, PREETISH | reporter.nih.gov |
| Role of miR125 in pulmonary hypertension secondary to interstitial lung disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,424,682 | December 1, 2019 | November 30, 2024 | EGHBALI, MANSOUREH | reporter.nih.gov |
| Lipid signaling in cellular senescence and tissue aging | NIH | National Institute on Aging | 2021 to 2024 | $1,411,976 | September 15, 2020 | June 30, 2025 | KRON, STEPHEN J. | reporter.nih.gov |
| Interventional Targeting of the IRE1alpha-TGFbeta signaling loop in pulmonary fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,405,838 | January 15, 2019 | December 31, 2023 | SHEPPARD, DEAN | reporter.nih.gov |
| WT1 REGULATION OF PULMONARY FIBROSIS | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $1,398,904 | May 22, 2017 | June 30, 2026 | MADALA, SATISH K | reporter.nih.gov |
| Targeting Lung Fibrosis Using Epigenetic Therapy | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,396,140 | August 15, 2024 | July 31, 2028 | BRAINSON, CHRISTINE FILLMORE | reporter.nih.gov |
| Cell Based Immunomodulation to Suppress Lung Inflammation and Promote Repair | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,392,522 | August 16, 2024 | July 31, 2028 | GHANTA, RAVI K | reporter.nih.gov |
| Predicting Post-Covid Pulmonary Fibrosis with Explainable Deep Learning and Optimal Biomarker Discovery | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,389,868 | September 1, 2024 | May 31, 2028 | BAGCI, ULAS | reporter.nih.gov |
| Regulation of Repair Responses in the Lung by Fatty Acid Oxidation | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,389,683 | June 17, 2024 | May 31, 2028 | MORA, ANA LUCIA | reporter.nih.gov |
| Platform technology to identify and develop first-in-class anti-fibrotic therapeutics through inhibition of collagen CP4H | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,377,583 | September 17, 2024 | August 31, 2027 | LENNOX, RONALD WILLIAM | reporter.nih.gov |
| Activation of matrix metalloproteinase-9 is essential to overcome failed fibrosis resolution | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,357,512 | April 1, 2024 | March 31, 2028 | REDENTE, ELIZABETH FRANCES | reporter.nih.gov |
| Non-catalytic FAK inhibitors as novel therapeutics for lung fibrosis | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,337,106 | August 10, 2022 | July 31, 2027 | MARLOWE, TIMOTHY A | reporter.nih.gov |
| Quantitative Ultrasound for Interstitial Lung Diseases | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,331,984 | September 17, 2024 | June 30, 2028 | MULLER, MARIE | reporter.nih.gov |
| Integrative, age-related changes in genome and epigenome in human lung in relation to smoking | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,327,731 | January 1, 2019 | December 31, 2023 | SPIVACK, SIMON D | reporter.nih.gov |
| Telomere Dysfunction as a cause of Chronic Lung Allograft Dysfunction | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $1,314,271 | May 15, 2020 | April 30, 2026 | GREENLAND, JOHN | reporter.nih.gov |
| Targeting dysfunctional epithelial repair in pulmonary fibrosis | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,302,038 | September 15, 2024 | June 30, 2028 | BLACKWELL, TIMOTHY S. | reporter.nih.gov |
| Role of lung endothelial cells during fibrotic lung remodeling. | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,289,853 | July 1, 2021 | September 15, 2023 | KALIN, TANYA | reporter.nih.gov |
| Intracellular Collagen Sensing in Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,285,843 | July 15, 2024 | June 30, 2029 | PODOLSKY, MICHAEL | reporter.nih.gov |
| Pathogenic Wnt-beta catenin target genes in macrophages and fibrosis | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2023 | $1,285,204 | July 3, 2019 | June 30, 2025 | HINCHCLIFF, MONIQUE EVANGELINE | reporter.nih.gov |
| Targeting chitin in fibrotic lung disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,265,340 | April 1, 2020 | March 31, 2025 | VAN DYKEN, STEVEN | reporter.nih.gov |
| Optimization of fibroblast-selective inhibitors of YAP/TAZ as novel therapeutics for Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $1,262,407 | February 1, 2022 | January 31, 2024 | HEYNEN-GENEL, SUSANNE | reporter.nih.gov |
| IDENTIFICATION AND PRECLINICAL EVALUATION OF NOVEL THERAPEUTIC APPROACHES TO DYSKERATOSIS CONGENITA | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,260,063 | July 1, 2019 | June 30, 2024 | JOHNSON, F. BRAD | reporter.nih.gov |
| Targeting the ADAM10-sEphrin-B2 pathway in pulmonary fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,260,000 | April 1, 2019 | March 31, 2026 | MEDOFF, BENJAMIN DAVID | reporter.nih.gov |
| Car4 regulates M2 macrophage responses and host protection to helminths | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,252,011 | June 7, 2024 | April 30, 2029 | SIRACUSA, MARK CHRISTOPHER | reporter.nih.gov |
| Mitochondrial metabolism controls alveolar epithelial cell fate | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,227,550 | September 1, 2024 | August 31, 2029 | HAN, SEUNGHYE | reporter.nih.gov |
| Metabolic Reprogramming of the Alveolar Stem Cell Niche in Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,213,153 | April 1, 2025 | March 31, 2028 | THANNICKAL, VICTOR J. | reporter.nih.gov |
| Advanced Imaging for Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,205,914 | September 1, 2024 | June 30, 2029 | MONTESI, SYDNEY | reporter.nih.gov |
| Encapsulation of mesenchymal stromal cells in engineered microgels for resolution of lung fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,199,250 | April 1, 2019 | March 31, 2025 | SHIN, JAE-WON | reporter.nih.gov |
| Adeno-associated virus-mediated SGPL1 gene therapy as a first-in-class treatment for idiopathic pulmonary fibrosis that acts by reducing sphingosine-1-phosphate and downstream profibrotic signaling | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,193,262 | January 15, 2025 | July 31, 2026 | SABA, JULIE D | reporter.nih.gov |
| Targeting Senescence Specific Mechanisms of NF-κB Activation to Reverse Chronic Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,178,040 | May 1, 2024 | February 28, 2029 | HAAK, ANDREW JON | reporter.nih.gov |
| Defining and targeting mechanisms of smoke-mediated fibrosis progression | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,177,500 | April 1, 2019 | March 31, 2026 | CHEN, CHING-HSIEN | reporter.nih.gov |
| Mechanoregulators of Nanoparticle-Cell Interactions at Tissue Interfaces | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $1,176,999 | September 1, 2023 | July 31, 2028 | MECKES, BRIAN R | reporter.nih.gov |
| Elucidating the Role of cGAS-STING in Lung Tissue Repair and Remodeling | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,152,984 | February 1, 2024 | January 31, 2028 | RIDGE, KAREN M | reporter.nih.gov |
| Inflammatory Injury Caused by Silica Exposure | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,147,500 | May 1, 2023 | April 30, 2027 | FU, JIAN | reporter.nih.gov |
| MYRF as an Entry Point to Study Mesothelium Function in Lung Development and Injury Repair | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,141,652 | February 1, 2024 | December 31, 2027 | SUN, XIN | reporter.nih.gov |
| Role of CXCR2-mediated cell trafficking in pulmonary vascular remodeling | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,127,945 | August 1, 2019 | July 31, 2025 | BRYANT, ANDREW JUSTIN | reporter.nih.gov |
| Tau Mediates Microtubule and Mitochondrial Dynamics to Control Cellular Organization and Alveolar Epithelial Repair | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,124,966 | August 10, 2024 | May 31, 2029 | TATA, ALEKSANDRA | reporter.nih.gov |
| IGF-II regulates lung fibrosis in scleroderma | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,121,250 | June 1, 2020 | May 31, 2025 | FEGHALI-BOSTWICK, CAROL A. | reporter.nih.gov |
| S100A4 Regulation of IPF Mesenchymal Progenitor Cell Fibrogenicity | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,115,272 | April 1, 2019 | March 31, 2024 | HENKE, CRAIG A | reporter.nih.gov |
| Inhalation Delivery of Exosome and microRNA Therapy for Lung Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $1,109,329 | June 15, 2022 | May 31, 2027 | DINH, PHUONG-UYEN C | reporter.nih.gov |
| Mapping Age-Related Changes in the Lung | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,102,168 | September 20, 2019 | June 30, 2025 | ROJAS, MAURICIO | reporter.nih.gov |
| Advanced tools for translation of intravenously-infused RNA LNP therapeutics to the clinic | NIH | National Center for Advancing Translational Sciences | 2024 | $1,084,194 | August 1, 2024 | May 31, 2026 | RAMUNAS, JOHN | reporter.nih.gov |
| Mechanosensing in lung fibrosis | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,074,798 | July 15, 2024 | June 30, 2028 | GARCIA, ANDRES J | reporter.nih.gov |
| Immune crosstalk in lung injury and fibrosis | NIH | National Heart, Lung, and Blood Institute | 2025 | $1,061,189 | January 1, 2025 | December 31, 2031 | MOORE, BETHANY B. | reporter.nih.gov |
| UNDERSTANDING CADHERIN-11 IN THE DEVELOPMENT AND TREATMENT OF LUNG FIBROSIS | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2024 to 2025 | $1,046,211 | February 10, 2024 | January 31, 2030 | AGARWAL, SANDEEP K | reporter.nih.gov |
| MTDNA HAPLOGROUPS IN BPD | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,036,046 | June 1, 2024 | March 31, 2029 | KANDASAMY, JEGEN | reporter.nih.gov |
| Elucidating tensin1-associated signals that promote fibronectin matrix assembly and lung fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,032,750 | April 1, 2019 | March 31, 2025 | SANDBO, NATHAN K | reporter.nih.gov |
| Precision MRI with Protein Contrast Agent for Noninvasive Detection of Lung Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2025 | $1,026,874 | September 15, 2023 | August 31, 2027 | YANG, JENNY J. | reporter.nih.gov |
| Targeting the Amino Acid Transporter SLC7A5 for Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,010,073 | May 1, 2024 | April 30, 2028 | CHOUDHURY, MALAY | reporter.nih.gov |
| An Agnostic, Host-Direct Survival Cure MCM for Pulmonary Toxicants. | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $999,601 | August 1, 2024 | July 31, 2025 | BUCK, MARTINA | reporter.nih.gov |
| Allergen Exposure Reduction as a Disease-Modifying Strategy in Allergen-Sensitized Children with Asthma | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $990,900 | September 1, 2021 | August 31, 2026 | GRANT, TORIE | reporter.nih.gov |
| Targeting CEBPA To Restore Epithelial-Mesenchymal Homeostasis In Lung Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $947,378 | July 15, 2020 | April 10, 2023 | TAN, QI | reporter.nih.gov |
| Pre-clinical development of a small molecule therapeutic for the systemic treatment of idiopathic pulmonary fibrosis | NIH | National Institute on Aging | 2025 | $943,301 | September 15, 2025 | August 31, 2027 | EVSEENKO, DENIS | reporter.nih.gov |
| Peptides for the treatment of pulmonary fibrosis | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $928,242 | August 21, 2024 | June 30, 2027 | FEGHALI-BOSTWICK, CAROL A. | reporter.nih.gov |
| WT1 REGULATION OF PULMONARY FIBROSIS | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $920,199 | May 22, 2017 | July 1, 2022 | MADALA, SATISH K | reporter.nih.gov |
| Targeting CEBPA To Restore Epithelial-Mesenchymal Homeostasis In Lung Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $906,772 | July 15, 2020 | June 30, 2026 | TAN, QI | reporter.nih.gov |
| Antidotes against HCI-induced chronic lung injury | NIH | National Institute of Environmental Health Sciences | 2021 to 2022 | $892,843 | August 20, 2020 | August 31, 2024 | CATRAVAS, JOHN D | reporter.nih.gov |
| IRE1α mediated dysregulation of the pulmonary epithelium in lung fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $873,990 | March 15, 2021 | February 28, 2026 | AUYEUNG, VINCENT CHURK-MAN | reporter.nih.gov |
| Role of lung endothelial cells during fibrotic lung remodeling | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $871,015 | July 1, 2021 | June 30, 2025 | KALIN, TANYA | reporter.nih.gov |
| Role of polyunsaturated fatty acids in pulmonary fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $858,060 | February 20, 2021 | January 31, 2026 | KIM, JOHN S | reporter.nih.gov |
| The Molecular Basis of the STIM/Orai Signaling Pathway | NIH | National Institute of General Medical Sciences | 2024 to 2025 | $834,000 | September 10, 2024 | August 31, 2029 | ZHOU, YANDONG | reporter.nih.gov |
| Computational Methods for Systems Genetic Analysis of Rare Polygenic Disorder | NIH | National Heart, Lung, and Blood Institute | 2024 | $827,753 | September 25, 2024 | August 31, 2025 | CHUN, SUNG | reporter.nih.gov |
| Epigenetic gene repression in pulmonary fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $825,000 | July 1, 2018 | June 30, 2024 | LIGRESTI, GIOVANNI | reporter.nih.gov |
| Pro-apoptotic Drugs as Host-Directed Treatments for Pulmonary Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $817,941 | August 1, 2024 | July 31, 2026 | JAIN, SANJAY | reporter.nih.gov |
| Leveraging multiomics and advanced mouse models to delineate mechanisms underlying sex‐specific differences in recovery and repair after neonatal hyperoxia exposure in the developing lung | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $817,521 | May 15, 2020 | April 30, 2025 | LINGAPPAN, KRITHIKA | reporter.nih.gov |
| YAP and TAZ regulate alveolar epithelial cell regeneration during lung repair | NIH | National Heart, Lung, and Blood Institute | 2025 | $811,370 | September 1, 2025 | August 31, 2030 | GOKEY, JASON JOSEPH | reporter.nih.gov |
| Oxidation-Specific Epitope IgA in Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2025 | $806,901 | August 1, 2025 | May 31, 2030 | STUREK, JEFFREY MICHAEL | reporter.nih.gov |
| Reconceptualizing Disease Progression in Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2025 | $797,845 | June 1, 2025 | March 31, 2030 | SALISBURY, MARGARET LOUISE | reporter.nih.gov |
| Hypoxia-induced aberrant lactate generation and shuttling serves as a direct signal to promote pro-fibrotic fibroblast phenotypes | NIH | National Heart, Lung, and Blood Institute | 2025 | $786,147 | February 1, 2025 | November 30, 2028 | HOROWITZ, JEFFREY C | reporter.nih.gov |
| Mechanisms underlying metal nanoparticle-induced lung injury and fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $781,145 | June 1, 2019 | May 31, 2025 | ZHANG, QUNWEI | reporter.nih.gov |
| Pro-apoptotic Drugs as Host-Directed Treatments for Pulmonary Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $774,881 | February 24, 2025 | November 30, 2025 | JAIN, SANJAY K | reporter.nih.gov |
| E-Box Accessibility in Myofibroblasts in Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2025 | $773,440 | January 1, 2025 | November 30, 2028 | KASS, DANIEL J | reporter.nih.gov |
| The Prognostic and Predictive Impact of Telomere Length in Fibrotic Interstitial Lung Disease | NIH | National Heart, Lung, and Blood Institute | 2025 | $771,751 | May 1, 2025 | February 28, 2030 | NEWTON, CHAD ALAN | reporter.nih.gov |
| Defining the biologic and physiologic trajectory of presymptomatic through advanced pulmonary fibrosis | NIH | National Heart, Lung, and Blood Institute | 2023 | $768,003 | September 11, 2023 | February 28, 2025 | SALISBURY, MARGARET LOUISE | reporter.nih.gov |
| The Role of Residential Bioaerosol Exposure in Pulmonary Sarcoidosis | NIH | National Heart, Lung, and Blood Institute | 2024 | $751,734 | September 24, 2024 | August 31, 2025 | GERKE, ALICIA | reporter.nih.gov |
| Investigating the Role of Radiation-induced Cell Death in Innate Lymphoid Cell Activation within Unique Tumor Microenvironments | NIH | National Cancer Institute | 2022 to 2024 | $747,000 | December 1, 2021 | March 31, 2026 | MCGEE, HEATHER MICHELLE | reporter.nih.gov |
| Engineered alveolar organoids to understand ECM signaling | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $746,991 | September 1, 2021 | August 31, 2025 | LOEBEL, CLAUDIA | reporter.nih.gov |
| Cellular and molecular delineation of pathologic fibroblasts in pulmonary fibrosis | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $746,848 | July 10, 2023 | June 30, 2026 | TSUKUI, TATSUYA | reporter.nih.gov |
| Purinergic Signaling in Fibroblast Activation and Lung Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2025 | $728,577 | August 1, 2025 | May 31, 2029 | BHATTACHARYA, MALLAR | reporter.nih.gov |
| Identifying predictors of treatment response in systemic sclerosis-related interstitial lung disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $728,264 | April 1, 2020 | March 31, 2026 | VOLKMANN, ELIZABETH R | reporter.nih.gov |
| Ribosome Dysfunction in Lung Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2025 | $722,667 | September 1, 2025 | May 31, 2030 | KARMOUTY-QUINTANA, HARRY | reporter.nih.gov |
| The Desmosome-Keratin Intermediate Filament Network in Lung Epithelial Injury, Repair and Regeneration | NIH | National Heart, Lung, and Blood Institute | 2025 | $722,584 | August 15, 2025 | May 31, 2029 | ZHOU, YONG | reporter.nih.gov |
| Unraveling idiopathic pulmonary fibrosis endophenotypes; a lung-centric approach to prognostic and therapeutic biomarker validation | NIH | National Heart, Lung, and Blood Institute | 2025 | $718,002 | September 15, 2025 | June 30, 2030 | MATSON, SCOTT MICHAEL | reporter.nih.gov |
| Molecular Markers of Idiopathic Pulmonary Fibrosis Progression | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $712,780 | June 1, 2020 | May 31, 2025 | NEWTON, CHAD ALAN | reporter.nih.gov |
| Vascular Leak and Outcomes in IPF | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $709,392 | April 1, 2020 | April 30, 2026 | MONTESI, SYDNEY | reporter.nih.gov |
| Role of Cdk9 in the Pathogenesis of Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2025 | $705,334 | January 1, 2025 | November 30, 2028 | HAUDENSCHILD, DOMINIK R | reporter.nih.gov |
| Defining cardinal functions of lung progenitors during regeneration | NIH | National Heart, Lung, and Blood Institute | 2025 | $701,795 | September 1, 2025 | June 30, 2029 | MORRISEY, EDWARD E | reporter.nih.gov |
| Microfibril-associated glycoproteins attenuating pulmonary fibrosis | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $700,328 | April 1, 2022 | March 31, 2027 | KOENITZER, JEFFREY | reporter.nih.gov |
| Fibroblast-mediated resolution of basal metaplasia in lung fibrosis | NIH | National Heart, Lung, and Blood Institute | 2025 | $695,421 | August 1, 2025 | April 30, 2029 | PENG, TIEN | reporter.nih.gov |
| Theraputic targeting of pulmonary endothelial cells to inhibit pathological lung remodeling | NIH | National Heart, Lung, and Blood Institute | 2025 | $695,403 | January 1, 2025 | November 30, 2028 | KALIN, TANYA | reporter.nih.gov |
| Functional Response Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease | NIH | National Heart, Lung, and Blood Institute | 2025 | $693,558 | September 1, 2025 | June 30, 2030 | VOLKMANN, ELIZABETH R | reporter.nih.gov |
| The gut-lung axis influences the development of bronchopulmonary dysplasia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $688,824 | July 1, 2020 | June 30, 2025 | WILLIS, KENT AVERY | reporter.nih.gov |
| Alveolar Epithelial Stress Signaling in Lung Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2025 | $683,564 | July 1, 2025 | March 31, 2030 | KATZEN, JEREMY BINDER | reporter.nih.gov |
| Role of visceral adipose tissue in frailty among patients with Idiopathic Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $683,424 | September 6, 2021 | August 31, 2025 | ANDERSON, MICHAELA RESTIVO | reporter.nih.gov |
| Syndecan-1 regulation of lung fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $682,992 | July 5, 2020 | June 30, 2025 | PARIMON, TANYALAK | reporter.nih.gov |
| Understanding how alveolar epithelial cell stress drives aberrant repair in interstitial lung disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $671,760 | July 1, 2020 | June 30, 2025 | KATZEN, JEREMY BINDER | reporter.nih.gov |
| Mitochondrial DNA and TLR9 in Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $671,760 | August 1, 2020 | July 31, 2025 | RYU, CHANGWAN | reporter.nih.gov |
| Regulation of disease progression by ER stress | NIH | National Heart, Lung, and Blood Institute | 2025 | $663,730 | August 20, 2025 | May 31, 2029 | CARTER, A BRENT | reporter.nih.gov |
| Improving Pulmonary Fibrosis Classification with Genomics Informed Phenotypic Clusters | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $648,448 | April 1, 2020 | March 31, 2025 | ADEGUNSOYE, AYODEJI | reporter.nih.gov |
| Proteomic markers of early and late stage pulmonary fibrosis | NIH | National Heart, Lung, and Blood Institute | 2025 | $644,997 | August 21, 2025 | May 31, 2030 | KIM, JOHN S | reporter.nih.gov |
| CD38, T cells and post viral lung sequelae during aging | NIH | National Institute on Aging | 2025 | $639,740 | December 15, 2024 | November 30, 2029 | SUN, JIE | reporter.nih.gov |
| Multimodal quantitative PET/MR imaging of pulmonary fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $633,884 | September 1, 2021 | August 31, 2025 | AKAM-BAXTER, EMAN | reporter.nih.gov |
| Macropinocytosis and Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2025 | $596,179 | January 1, 2025 | December 31, 2025 | TSOYI, KONSTANTIN | reporter.nih.gov |
| Optimization of fibroblast-selective inhibitors of YAP/TAZ as novel therapeutics for Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2024 | $596,061 | May 1, 2024 | April 30, 2026 | HEYNEN-GENEL, SUSANNE | reporter.nih.gov |
| Mechano-niche in Lung Repair after Injury | NIH | National Heart, Lung, and Blood Institute | 2024 | $595,823 | June 15, 2021 | May 31, 2026 | ZHOU, YONG | reporter.nih.gov |
| A Novel, Host-Directed Therapeutic for the Treatment of Sulfur Mustard Induced Lung Injury | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $595,708 | July 9, 2024 | December 31, 2026 | VERESS, LIVIA AGNES | reporter.nih.gov |
| Discovering Extracellular Modulators of Lung Fibrogenesis by Profiling Newly Synthesized Extracellular Matrix | NIH | National Heart, Lung, and Blood Institute | 2022 | $595,604 | September 20, 2022 | August 31, 2024 | REN, XI | reporter.nih.gov |
| Sox9 Regulation of Fibroblast Activation and Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $574,472 | August 15, 2021 | July 1, 2022 | MADALA, SATISH K | reporter.nih.gov |
| Complement Pathway Activation in Idiopathic Pulmonary Fibrosis and other Progressive Fibrosing Interstitial Lung Diseases | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $567,756 | February 1, 2023 | January 31, 2028 | SWAMINATHAN, APARNA CHANDRA | reporter.nih.gov |
| Development of YK-4-250, a radiation mitigator of GI-ARS | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $552,787 | April 25, 2025 | March 31, 2030 | BROWN, MILTON L. | reporter.nih.gov |
| Screening of novel compounds through the reversal of gene expression in idiopathic pulmonary fibrosis | NIH | National Heart, Lung, and Blood Institute | 2025 | $542,402 | April 1, 2025 | March 31, 2027 | LI, XIAOPENG | reporter.nih.gov |
| Bromodomain-containing Protein 4 in Profibrotic Gene Expression and Lung Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $533,681 | February 1, 2024 | January 31, 2027 | SANDERS, YAN | reporter.nih.gov |
| Validation of a microRNA panel to pre-symptomatically predict the risk of radiation-induced fibrosis | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $533,384 | September 2, 2025 | August 31, 2030 | ROGERS, CLAUDE J. | reporter.nih.gov |
| Quantitative MRI-PET Imaging of Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $531,579 | September 25, 2020 | June 30, 2024 | ZHOU, IRIS YUWEN | reporter.nih.gov |
| Role of the Novel MicroRNA-125b in Pulmonary Hypertension Associated with Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $527,472 | May 1, 2019 | April 30, 2024 | UMAR, SOBAN | reporter.nih.gov |
| Mechanisms of Impaired Epithelial Regeneration and Fibrosis After Silica Dust Inhalation | NIH | National Institute of Environmental Health Sciences | 2024 | $527,300 | September 1, 2024 | June 19, 2025 | ZEMANS, RACHEL LYNNE | reporter.nih.gov |
| Mechanisms of Impaired Epithelial Regeneration and Fibrosis After Silica Dust Inhalation | NIH | National Institute of Environmental Health Sciences | 2025 | $526,627 | June 20, 2025 | March 31, 2030 | ZEMANS, RACHEL LYNNE | reporter.nih.gov |
| Antifibrotic effects of Syndecan-2 and CD148 in Rheumatoid Arthritis Interstitial Lung Disease | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2024 | $523,800 | May 1, 2020 | April 30, 2025 | TSOYI, KONSTANTIN | reporter.nih.gov |
| Senolytics to Improve Cognition and Mobility in Older Adults at Risk of Alzheimer’s Disease | NIH | National Institute on Aging | 2021 to 2022 | $518,406 | September 15, 2021 | May 31, 2023 | LIPSITZ, LEWIS | reporter.nih.gov |
| Engineered Monothiol Thioredoxin for Treatment of Radiation Induced Lung Injury | NIH | National Heart, Lung, and Blood Institute | 2025 | $508,988 | September 24, 2025 | August 31, 2026 | HEIFETZ, PETER B | reporter.nih.gov |
| Lung Myofibroblast De-Differentiation and Fibrosis Resolution Depend on cAMP-mediated Inhibition of HuR. | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $508,680 | April 15, 2023 | February 29, 2028 | FORTIER, SEAN MICHAEL | reporter.nih.gov |
| Targeting the Amino Acid Transporter SLC7A5 for Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2023 | $501,021 | May 15, 2023 | January 16, 2024 | CHOUDHURY, MALAY | reporter.nih.gov |
| Role of Endo180 Regulation in Tissue Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $498,234 | August 15, 2019 | July 31, 2024 | PODOLSKY, MICHAEL | reporter.nih.gov |
| Defining the molecular determinants of mesenchymal lineage allocation in lung development and disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $498,000 | September 1, 2020 | August 31, 2024 | ZEPP, JAROD | reporter.nih.gov |
| Toll-like Receptors and Respiratory Microbiota Interactions in Idiopathic Pulmonary | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $497,998 | January 1, 2018 | December 31, 2022 | O'DWYER, DAVID NOEL | reporter.nih.gov |
| Host Response, Lung Microbiome, and Clinical Phenotype in Hypersensitivity Pneumonia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $487,290 | April 1, 2019 | February 29, 2024 | SALISBURY, MARGARET LOUISE | reporter.nih.gov |
| Utilizing induced pluripotent stem cells to study the role of alveolar type 2 cell dysfunction in pulmonary fibrosis | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $486,648 | January 1, 2023 | December 31, 2027 | ALYSANDRATOS, KONSTANTINOS | reporter.nih.gov |
| Phosphorylation Control of Fibroproliferative ARDS | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $486,009 | August 1, 2019 | November 30, 2024 | ASCHNER, YAEL | reporter.nih.gov |
| New Advanced Engineering Tools for Investigating Lung Injury and Repair | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $478,187 | December 15, 2021 | February 29, 2024 | CHIOCCIOLI, MAURIZIO | reporter.nih.gov |
| Lung fibrosis impairs tumor immunity and limits immune checkpoint efficacy | NIH | National Cancer Institute | 2024 to 2025 | $463,740 | June 12, 2024 | May 31, 2029 | HERZOG, BRETT HOWARD | reporter.nih.gov |
| Targeting Isoform-specific FGFR Signaling in Idiopathic Pulmonary Fibrosis | NIH | National Institute on Aging | 2025 | $461,146 | May 15, 2025 | April 30, 2027 | LEE, SANGWON | reporter.nih.gov |
| Radioresistant Innate Immunity in SAVI Tissue-Specific Autoinflammation | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $460,625 | August 4, 2023 | July 31, 2025 | MARSHAK-ROTHSTEIN, ANN | reporter.nih.gov |
| Reverse electron transport inhibition to suppress fibroblast activation in aging | NIH | National Institute on Aging | 2025 | $460,283 | September 1, 2025 | August 31, 2027 | BHATTACHARYA, MALLAR | reporter.nih.gov |
| TREM-1 therapy for the treatment of empyema | NIH | National Heart, Lung, and Blood Institute | 2025 | $457,954 | September 15, 2025 | August 30, 2026 | SIGALOV, ALEXANDER B | reporter.nih.gov |
| Investigation of Dpp9 in COVID19 | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $454,081 | June 9, 2023 | May 31, 2025 | FLAVELL, RICHARD A | reporter.nih.gov |
| Phase 1 study of oral epigallocatechin-3-gallate (EGCG) in IPF patients | NIH | National Heart, Lung, and Blood Institute | 2022 | $453,796 | May 20, 2022 | April 30, 2023 | MARTINEZ, FERNANDO J | reporter.nih.gov |
| Development of Novel Small Molecule Anti-Fibrotic Agent for the Treatment of Systemic Scleroderma | NIH | National Heart, Lung, and Blood Institute | 2023 | $452,422 | September 15, 2023 | August 31, 2025 | ALEGRIA, ESTHER M | reporter.nih.gov |
| Cellular Immunotherapy to Combat Fibrosis and Inflammation in Systemic Sclerosis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $450,136 | June 1, 2023 | September 30, 2025 | PIOLI, PATRICIA A. | reporter.nih.gov |
| Fibroblast activating protein PET-CT imaging of TB-associated fibrosis | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $446,875 | August 26, 2025 | July 31, 2027 | BISSON, GREGORY P. | reporter.nih.gov |
| Understanding SHRF, an RNA exosome-linked disease with multi-organ involvement | NIH | Office of the Director, National Institutes of Health | 2021 to 2022 | $433,132 | December 1, 2020 | November 30, 2022 | LU, BINGWEI | reporter.nih.gov |
| LTBP2 regulation of fibrotic lung damage | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $430,834 | June 2, 2022 | May 31, 2025 | ORNITZ, DAVID M | reporter.nih.gov |
| Genomic Basis of Telomere Length Regulation and Consequences for Complex Traits | NIH | National Institute on Aging | 2024 | $430,101 | September 15, 2024 | August 31, 2025 | COGAN, JOY D | reporter.nih.gov |
| DUOX1 in fibroblast-macrophage cross-talk in pulmonary fibrosis | NIH | National Institute on Aging | 2022 to 2023 | $429,000 | January 1, 2022 | November 30, 2024 | VAN DER VLIET, ALBERT | reporter.nih.gov |
| Chitin and chitinases in SARS-CoV-2 infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $427,834 | June 1, 2023 | May 31, 2025 | VAN DYKEN, STEVEN | reporter.nih.gov |
| Src Homology and Collagen (Shc) inhibition for the treatment of transplant-related pulmonary fibrosis. | NIH | National Center for Advancing Translational Sciences | 2025 | $427,392 | July 2, 2025 | June 30, 2027 | HSU, JOE L | reporter.nih.gov |
| Targeting macrophages to reduce the combined injury effects of radiation and virus exposure | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $423,500 | May 5, 2022 | April 30, 2024 | MARPLES, BRIAN | reporter.nih.gov |
| Mitigation of Chlorine Injury to Mitochondria | NIH | National Institute of Environmental Health Sciences | 2021 to 2022 | $421,688 | September 4, 2021 | August 31, 2023 | MATALON, SADIS | reporter.nih.gov |
| Crosstalk between CES1 and PPAR gamma and LXR alpha in macrophages | NIH | National Heart, Lung, and Blood Institute | 2022 | $420,691 | February 15, 2022 | January 31, 2026 | ROSS, MATTHEW K | reporter.nih.gov |
| CD8+ T Cell Dysfunction Promotes Sarcoidosis Progression | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $408,750 | March 15, 2019 | January 31, 2024 | CELADA, LINDSAY JOHANA | reporter.nih.gov |
| Inhibition of Histone Deacetylase 8 (HDAC8) as a Therapy for Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $405,000 | May 15, 2020 | April 30, 2025 | SAITO, SHIGEKI | reporter.nih.gov |
| Inhalation Delivery of Exosome and microRNA Therapy for Lung Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2025 | $404,462 | June 1, 2025 | May 31, 2027 | ZHU, DASHUAI | reporter.nih.gov |
| Regulation of Silica-induced Lung Injury by Plasminogen Activator Inhibitor-1 | NIH | National Institute of Environmental Health Sciences | 2022 | $404,250 | September 20, 2022 | August 31, 2025 | SHETTY, SREERAMA | reporter.nih.gov |
| Development of Protein MRI Contrast Agent for Precision Imaging Lung Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2024 | $401,613 | May 15, 2024 | April 30, 2025 | YANG, JENNY J. | reporter.nih.gov |
| Wnt Signaling in Bronchopulmonary Dysplasia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $400,227 | August 15, 2019 | July 31, 2024 | SUCRE, JENNIFER MALCOLMSRYGLEY | reporter.nih.gov |
| A fully automated tool for more accurate malignancy assessment in pulmonary nodules from chest CT | NIH | National Cancer Institute | 2025 | $399,112 | August 1, 2025 | July 31, 2026 | REICHER, JOSHUA | reporter.nih.gov |
| TT-036 for the treatment of scleroderma-associated pulmonary fibrosis | NIH | National Heart, Lung, and Blood Institute | 2024 | $389,754 | September 5, 2024 | September 4, 2025 | FEGHALI-BOSTWICK, CAROL A. | reporter.nih.gov |
| Contribution of Macropinocytosis in fibroblast activation and systemic sclerosis | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2023 | $387,200 | February 1, 2022 | December 31, 2023 | TSOYI, KONSTANTIN | reporter.nih.gov |
| Clinical Trial Readiness - Primary Ciliary Dyskinesia (CTR-PCD) | NIH | National Center for Advancing Translational Sciences | 2022 to 2023 | $381,588 | July 1, 2022 | June 30, 2025 | ROSENFELD, MARGARET | reporter.nih.gov |
| Rare Airway Cell Function in Post-Viral Chronic Inflammation | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $380,024 | May 1, 2024 | June 30, 2026 | BARR, JUSTINN | reporter.nih.gov |
| Development of Protein MRI Contrast Agent for Precision Imaging Lung Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2025 | $373,613 | May 15, 2024 | April 30, 2027 | YANG, JENNY J. | reporter.nih.gov |
| Quantitative Optical Imaging Biomarkers of Interstitial Lung Disease | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $373,360 | April 1, 2024 | March 31, 2029 | NANDY, SREYANKAR | reporter.nih.gov |
| The Role of Hematopoietic Loss of Y Chromosome on Aging Phenotypes | NIH | National Institute on Aging | 2024 to 2025 | $372,816 | July 1, 2024 | June 30, 2027 | CHAVKIN, NICHOLAS W | reporter.nih.gov |
| Understanding Mechanisms Driving Poor Outcomes in Women with Dermatomyositis | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2025 | $366,639 | September 5, 2025 | August 31, 2029 | CHARLES-SCHOEMAN, CHRISTINA | reporter.nih.gov |
| Role of Surfactant Protein-C Mutation and Ozone Exposure in the Exacerbation of Pulmonary Fibrosis | NIH | National Institute of Environmental Health Sciences | 2025 | $364,398 | September 19, 2025 | November 30, 2026 | VENOSA, ALESSANDRO | reporter.nih.gov |
| Feasibility and Acceptability of A Mobile Application "SUPPORT-T" to increase access of Palliative Care in patients with Progressive Pulmonary Fibrosis (PPF) and their caregivers | NIH | National Heart, Lung, and Blood Institute | 2025 | $355,530 | August 20, 2025 | August 31, 2027 | LINDELL, KATHLEEN OARE | reporter.nih.gov |
| Pathways regulating profibrotic macrophages in a novel explant model of systemic sclerosis-associated interstitial lung disease | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2024 to 2025 | $347,560 | September 6, 2024 | August 31, 2026 | LAFYATIS, ROBERT A. | reporter.nih.gov |
| Role and regulation of vascular permeability in pulmonary fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $345,600 | August 5, 2018 | July 31, 2023 | KNIPE, RACHEL S | reporter.nih.gov |
| Bromodomain-containing Protein 4 in Profibrotic Gene Expression and Lung Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2024 | $343,311 | February 1, 2024 | June 30, 2024 | SANDERS, YAN | reporter.nih.gov |
| Role of High Density Lipoproteins in Interstitial Lung Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $343,224 | September 2, 2020 | December 31, 2024 | PODOLANCZUK, ANNA | reporter.nih.gov |
| Mentoring in Translational Research in Interstitial Lung Diseases | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $341,889 | February 15, 2016 | December 31, 2026 | DRAKE, WONDER P. | reporter.nih.gov |
| Characterization of Early Response to Chronic Lung Injury using Chest CT | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $340,640 | January 1, 2019 | December 3, 2022 | ASH, SAMUEL | reporter.nih.gov |
| Progression of interstitial lung abnormalities: the role of imaging and telomere length regulation | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $340,640 | January 19, 2018 | December 31, 2023 | PUTMAN, RACHEL | reporter.nih.gov |
| Risk-stratification and prediction of adverse outcomes in interstitial lung abnormalities | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $334,820 | April 1, 2024 | March 31, 2029 | ROSE, JONATHAN | reporter.nih.gov |
| Novel Orally Available CBP/Beta-Catenin Antagonists to Treat Idiopathic Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2022 | $334,008 | March 5, 2022 | February 29, 2024 | HAFFAR, OMAR | reporter.nih.gov |
| Multi-omic profiling of IPF endotypes | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $331,484 | April 1, 2024 | March 31, 2029 | ZHANG, DA | reporter.nih.gov |
| Mechanosignaling regulates macrophage immunometabolism | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $328,752 | April 1, 2023 | January 31, 2028 | HE, CHAO | reporter.nih.gov |
| Inhibition of Fgr Prevents Pulmonary Fibrosis | NIH | National Institute on Aging | 2023 | $325,950 | September 15, 2023 | August 31, 2025 | MUKHERJEE, AMITAVA | reporter.nih.gov |
| Regulatory role of APA in pulmonary fibrosis during aging | NIH | National Institute on Aging | 2022 | $319,800 | September 30, 2022 | August 31, 2024 | MILLS, TINGTING WENG | reporter.nih.gov |
| An oxysterol drug candidate, Oxy210, for inhibition of pulmonary fibrosis through targeting hedgehog and TGFβ signaling | NIH | National Heart, Lung, and Blood Institute | 2022 | $318,089 | August 10, 2022 | July 31, 2024 | PARHAMI, FARHAD | reporter.nih.gov |
| Cellular and molecular delineation of pathologic fibroblasts in pulmonary fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $315,360 | August 5, 2021 | June 30, 2023 | TSUKUI, TATSUYA | reporter.nih.gov |
| Arthrofibrosis control using small molecule inhibitors of interleukin-11 | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2025 | $314,362 | September 22, 2025 | August 31, 2027 | SWINDLEHURST, CATHY A | reporter.nih.gov |
| Bcl-2 dependent fibroblast resistance to apoptosis occurs through persistent IL-6 signaling | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $313,632 | July 15, 2024 | June 30, 2029 | COOLEY, JOSEPH CHARLES | reporter.nih.gov |
| High-throughput spatial proteomics in pulmonary research with FLASH multiplex imaging | NIH | National Heart, Lung, and Blood Institute | 2025 | $312,148 | August 1, 2025 | July 31, 2026 | M'SAAD, ONS | reporter.nih.gov |
| Repurposing Pyrvinium as an Inhalation Therapy for Idiopathic Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2025 | $309,418 | September 20, 2025 | August 31, 2026 | CARDELLI, JAMES | reporter.nih.gov |
| Myocardin-related transcription factor (MRTF) pathway modulators as a novel, disease-modifying oral medicine for idiopathic pulmonary fibrosis (IPF) | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $307,583 | May 1, 2024 | October 31, 2025 | GOLEBIOWSKI, ADAM | reporter.nih.gov |
| Novel oral small molecules for progressive pulmonary fibrosis | NIH | National Heart, Lung, and Blood Institute | 2024 | $306,872 | September 20, 2024 | February 28, 2026 | SWINDLEHURST, CATHY A | reporter.nih.gov |
| Stiffness measurements in human lung slices to evaluate therapeutic and preventive potentials of anti-fibrotic drugs | NIH | National Heart, Lung, and Blood Institute | 2024 | $306,748 | September 17, 2024 | September 16, 2025 | KIM, JAE HUN | reporter.nih.gov |
| Development of a Novel Therapeutic Agent for Skin Fibrosis | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2024 | $306,518 | September 20, 2024 | August 31, 2025 | BOGATKEVICH, GALINA S | reporter.nih.gov |
| Pulmonary Surface Irregularity score: A Quantitative CT Biomarker for Idiopathic Pulmonary Fibrosis | NIH | National Institute of General Medical Sciences | 2021 to 2022 | $306,499 | September 23, 2021 | August 31, 2022 | JACOBUS, ROBERT B | reporter.nih.gov |
| Frontiers at the edge: Subpleural fibroblasts orchestrate pulmonary fibrosis progression | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $306,260 | June 1, 2024 | March 31, 2026 | XU, LE | reporter.nih.gov |
| Development of Novel Regenerative Cell Therapies for Lung Diseases using AI-guided Chemical Reprogramming of Human Cells | NIH | National Heart, Lung, and Blood Institute | 2024 | $306,239 | April 15, 2024 | June 30, 2025 | IETSWAART, JALDERT HUGO RIGOBERT | reporter.nih.gov |
| The development of a STAT3 inhibitor for lung scleroderma | NIH | National Heart, Lung, and Blood Institute | 2024 | $299,999 | May 15, 2024 | April 30, 2026 | OZES, ALI RAYET | reporter.nih.gov |
| TERT mRNA lipid nanoparticles to extend telomeres to treat pulmonary fibrosis | NIH | National Heart, Lung, and Blood Institute | 2022 | $299,987 | September 25, 2022 | July 31, 2023 | RAMUNAS, JOHN | reporter.nih.gov |
| Novel Therapeutics for Interstitial Lung Disease: Modified, Water-Soluble Caveolin-1 Scaffolding Domain Peptides with Improved Characteristics for Drug Development | NIH | National Heart, Lung, and Blood Institute | 2022 | $299,930 | August 1, 2022 | July 31, 2024 | HOFFMAN, STANLEY R | reporter.nih.gov |
| Non-catalytic FAK inhibitors as novel therapeutics for lung fibrosis | NIH | National Heart, Lung, and Blood Institute | 2022 | $299,905 | August 10, 2022 | July 31, 2024 | MARLOWE, TIMOTHY A | reporter.nih.gov |
| Development of a targeted TGF-b therapeutic that selectively blocks lung fibrosis in idiopathic pulmonary fibrosis (IPF) patients | NIH | National Heart, Lung, and Blood Institute | 2023 | $299,900 | June 1, 2023 | May 31, 2024 | THOMAS-KARYAT, DORI A | reporter.nih.gov |
| Preclinical Development of a Novel Therapeutic Agent for Idiopathic Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2023 | $299,295 | August 15, 2023 | July 31, 2025 | BOGATKEVICH, GALINA S | reporter.nih.gov |
| The development of a transcriptional inhibitor for lung fibrosis. | NIH | National Heart, Lung, and Blood Institute | 2022 | $299,068 | June 1, 2022 | May 31, 2024 | OZES, ALI RAYET | reporter.nih.gov |
| Precision MRI with a Novel Protein Contrast Agent for Early Detection and Staging of Lung Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2023 | $298,840 | September 15, 2023 | August 31, 2025 | YANG, JENNY J. | reporter.nih.gov |
| Epigenetic editor therapeutics | NIH | National Institute of General Medical Sciences | 2025 | $298,530 | July 1, 2025 | June 30, 2027 | FEDULOV, ALEXEY V | reporter.nih.gov |
| Development of BIO 300 as a novel treatment for idiopathic pulmonary fibrosis | NIH | National Heart, Lung, and Blood Institute | 2023 | $298,474 | September 1, 2023 | April 30, 2025 | KAYTOR, MICHAEL D | reporter.nih.gov |
| Validation of APT101 for the Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) in an Aging Murine Model | NIH | National Institute on Aging | 2025 | $292,279 | September 20, 2025 | May 31, 2027 | WILLETTE, ROBERT N | reporter.nih.gov |
| Repurposing of FDA-approved Nrf2 Activators as a Novel Inhaled Therapy for Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2024 | $286,739 | May 15, 2024 | May 14, 2026 | HECKER, LOUISE | reporter.nih.gov |
| Targeting eNAMPT-TLR4 signaling with the novel ALT-100 mAb to slow IPF progression | NIH | National Heart, Lung, and Blood Institute | 2025 | $284,699 | September 20, 2025 | September 19, 2026 | MIELE, STANLEY | reporter.nih.gov |
| Recombinant human CC10 protein for treatment and prevention of chronic lung allograft dysfunction | NIH | National Heart, Lung, and Blood Institute | 2023 | $260,664 | August 5, 2023 | August 4, 2025 | PILON, APRILE L | reporter.nih.gov |
| Optimization and development of extracellular matrix-targeting probes for PET-based assessment of lung fibrosis disease activity | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $260,643 | September 1, 2024 | August 31, 2029 | BERNAU, KSENIJA | reporter.nih.gov |
| Development of Modified Caveolin-1 Scaffolding Domain Peptides with Improved Pharmacological Properties as Therapeutic Agents for Scleroderma Skin Disease | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 | $259,601 | September 1, 2022 | August 31, 2024 | HOFFMAN, STANLEY R | reporter.nih.gov |
| The Development of CSD peptides for the therapeutic treatment of post-acute sequelae of COVID-19 (PACS) | NIH | National Heart, Lung, and Blood Institute | 2023 | $259,332 | September 15, 2023 | July 31, 2024 | MACKENZIE, BREANNE | reporter.nih.gov |
| Investigation of pulmonary fibrosis biology in pediatric hematopoietic cell transplant patients | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $252,843 | August 15, 2024 | July 31, 2026 | ZINTER, MATTHEW SCOTT | reporter.nih.gov |
| Elucidating the epigenetic regulation of extracellular matrix and virus-induced fibroblast activation | NIH | National Institute of General Medical Sciences | 2023 to 2024 | $250,000 | February 1, 2023 | January 31, 2025 | GARDINER, JAYE C | reporter.nih.gov |
| Common and distinct metabolic pathways of pulmonary sarcoidosis phenotypes and endotypes | NIH | National Heart, Lung, and Blood Institute | 2025 | $249,000 | July 1, 2025 | June 30, 2027 | LIAO, SHU-YI | reporter.nih.gov |
| Elucidating the epigenetic regulation of extracellular matrix and virus-induced fibroblast activation | NIH | National Institute of General Medical Sciences | 2025 | $249,000 | September 15, 2025 | September 14, 2028 | GARDINER, JAYE C | reporter.nih.gov |
| Mechanotransduction regulation of cellular metabolism in pulmonary fibrosis | NIH | National Heart, Lung, and Blood Institute | 2025 | $248,999 | September 1, 2025 | August 31, 2028 | THOMAS FREEBERG, MARGARET | reporter.nih.gov |
| Validation of a CD206-targeted PET imaging probe for pulmonary fibrosis | NIH | National Heart, Lung, and Blood Institute | 2025 | $247,500 | August 15, 2025 | July 31, 2027 | WANG, CUIHUA | reporter.nih.gov |
| Characterizing a novel mouse model linking sphingolipid metabolism to multi-organ fibrosis | NIH | Office of the Director, National Institutes of Health | 2025 | $246,000 | July 15, 2025 | April 30, 2027 | SABA, JULIE D | reporter.nih.gov |
| Unsupervised Machine Learning to Identify Unique Clusters of Systemic Sclerosis Pulmonary Hypertension Patients | NIH | National Heart, Lung, and Blood Institute | 2025 | $245,624 | September 5, 2025 | August 31, 2027 | LAMMI, MATTHEW R | reporter.nih.gov |
| Quantitative magnetic resonance imaging of pulmonaryperfusion | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $245,576 | September 15, 2024 | June 30, 2027 | ZHOU, IRIS YUWEN | reporter.nih.gov |
| IL-17A mRNA-targeted oligonucleotide therapeutics in Idiopathic Pulmonary Fibrosis (IPF) | NIH | National Heart, Lung, and Blood Institute | 2023 | $245,000 | August 18, 2023 | July 31, 2025 | RAMGOLAM, VINOD SATISCH | reporter.nih.gov |
| Air Pollution, Environmental Injustice and Progressive Pulmonary Fibrosis | NIH | National Institute of Environmental Health Sciences | 2025 | $241,811 | January 1, 2025 | December 31, 2029 | MACMURDO, MAEVE GEORGIA | reporter.nih.gov |
| Epigenetic Regulation of KLF4 in SSc-associated lung fibrosis | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2024 to 2025 | $239,972 | May 15, 2024 | April 30, 2029 | RENAUD, LUDIVINE | reporter.nih.gov |
| Fibronectin Extra Domain A Degradation as an Antifibrotic Approach in Lung Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $236,140 | April 1, 2024 | March 31, 2026 | EVANKOVICH, JOHN W | reporter.nih.gov |
| RECK in Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2025 | $229,500 | August 1, 2025 | July 31, 2027 | SAITO, SHIGEKI | reporter.nih.gov |
| Mentoring in Translational Research in Interstitial Lung Diseases | NIH | National Heart, Lung, and Blood Institute | 2022 | $227,894 | February 15, 2016 | December 31, 2023 | DRAKE, WONDER P. | reporter.nih.gov |
| CSP7 inhibits toxicity of ionizing radiation to the lung | NIH | National Cancer Institute | 2025 | $219,024 | July 1, 2025 | June 30, 2027 | SHETTY, SREERAMA | reporter.nih.gov |
| Next-generation ultrafast functional 3D pulmonary imaging | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $209,784 | September 7, 2021 | September 6, 2024 | ARIYASINGHA U W, NUWANDI M | reporter.nih.gov |
| B Cell-Fibroblast Crosstalk Promotes Chronic GVHD of the Lung | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $208,126 | July 1, 2024 | August 31, 2026 | BRACKEN, SONALI JAGDISH | reporter.nih.gov |
| Investigating the link between propionate metabolism and aging | NIH | National Institute on Aging | 2024 to 2025 | $203,850 | August 1, 2024 | July 31, 2026 | LI, ZHONGCHI | reporter.nih.gov |
| Extracellular matrix stiffness control of NLRP3 inflammasome activity | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $197,160 | July 1, 2025 | September 26, 2025 | OKIN, DANIEL | reporter.nih.gov |
| Targeting the Amino Acid Transporter SLC7A5 for Treatment of Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2022 | $195,732 | September 7, 2022 | January 16, 2024 | CHOUDHURY, MALAY | reporter.nih.gov |
| Developing an exosomic signature of rapidly progressive idiopathic pulmonary fibrosis | NIH | National Heart, Lung, and Blood Institute | 2025 | $193,378 | January 1, 2025 | July 15, 2025 | ECKHARDT, CHRISTINA M | reporter.nih.gov |
| Hyperpolarized Xenon-129 MRI as a predictive biomarker for mitigating radiation-induced lung injury | NIH | National Heart, Lung, and Blood Institute | 2025 | $191,913 | July 28, 2025 | June 30, 2030 | NIEDZIELSKI, JOSHUA | reporter.nih.gov |
| Understanding Pulmonary Fibrosis Through the Integration of Complex Occupational and Environmental Exposure Assessments (PF-OEM) | NIH | National Heart, Lung, and Blood Institute | 2025 | $190,998 | August 1, 2025 | July 31, 2030 | GANDHI, SHEIPHALI ARVIND | reporter.nih.gov |
| Reprogramming of type 2 alveolar epithelial cells in idiopathic pulmonary fibrosis and regulation by TGFb1. | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $189,278 | January 1, 2022 | June 30, 2023 | COHEN, MAX LOUIS | reporter.nih.gov |
| Role of Aldehyde Dehydrogenase 2 in Resolution of Fibroproliferative ARDS | NIH | National Heart, Lung, and Blood Institute | 2025 | $189,000 | August 1, 2025 | July 31, 2027 | ASCHNER, YAEL | reporter.nih.gov |
| Determining the role of CD163+ blood monocytes and lung macrophages in Progressive Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2025 | $188,892 | August 1, 2025 | July 31, 2030 | HOLTON, SARAH ELIZABETH | reporter.nih.gov |
| Fibrotic remodeling of lymph nodes disrupts T cell function in fibrosis and cancer | NIH | National Cancer Institute | 2024 to 2025 | $182,098 | January 1, 2024 | May 18, 2025 | BINGHAM, GRACE C | reporter.nih.gov |
| Application of single-cell trajectory analysis in single-cell transcriptomics to elucidate the biology of lung pericytes in injury, repair, and regeneration | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $176,500 | December 15, 2021 | November 30, 2023 | HUNG, CHI F | reporter.nih.gov |
| Multi-Omics Approaches for the Diagnosis and Risk Stratification of Pulmonary Fibrosis-Associated Pulmonary Hypertension | NIH | National Heart, Lung, and Blood Institute | 2025 | $175,392 | August 1, 2025 | July 31, 2030 | BROWNSTEIN, ADAM JOSEPH | reporter.nih.gov |
| Defining Combined Pulmonary Fibrosis and Emphysema (CPFE) using Quantitative CT Imaging | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $173,667 | September 10, 2024 | July 9, 2026 | WANG, JENNIFER MIN | reporter.nih.gov |
| Uncovering the Inflammatory-Fibrotic Axis in Pulmonary Sarcoidosis | NIH | National Heart, Lung, and Blood Institute | 2025 | $173,480 | September 20, 2025 | August 31, 2030 | VAGTS, CHRISTEN | reporter.nih.gov |
| Identifying Disease-Specific Immune Cell Shifts in Chronic Fibrotic Interstitial Lung Diseases with Single-Cell RNA Sequencing | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $172,728 | February 16, 2022 | February 15, 2026 | ZHAO, AMY YUE-TING | reporter.nih.gov |
| Epigenetic signatures driving metaplastic repair mechanisms in human alveolar type II cells | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $172,724 | September 30, 2024 | September 29, 2027 | IANTORNO, STEFANO AZELIO | reporter.nih.gov |
| Mechanotransduction regulation of cellular metabolism in pulmonary fibrosis | NIH | National Heart, Lung, and Blood Institute | 2024 | $170,543 | September 1, 2024 | August 31, 2026 | THOMAS FREEBERG, MARGARET | reporter.nih.gov |
| Alveolar macrophage and epithelial cell lipid metabolism in pulmonary fibrosis | NIH | National Heart, Lung, and Blood Institute | 2025 | $169,992 | August 15, 2025 | July 31, 2030 | WATSON, RICHARD L. | reporter.nih.gov |
| Histologic and Transcriptional Profiling of Endothelial Cells During Progressive Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $166,640 | May 1, 2022 | April 30, 2024 | KNIPE, RACHEL S | reporter.nih.gov |
| Role of Protein S-Palmitoylation in TGFbeta Signaling and Fibrotic Lung Disease | NIH | National Heart, Lung, and Blood Institute | 2025 | $165,456 | August 15, 2025 | June 30, 2030 | FORRESTER, MICHAEL T | reporter.nih.gov |
| Mechanosignaling regulates macrophage immunometabolism | NIH | National Heart, Lung, and Blood Institute | 2025 | $164,376 | April 1, 2023 | January 31, 2028 | HE, CHAO | reporter.nih.gov |
| Aging and Metabolic Dysfunction Drive Disrupted Alveolar Epithelial Progenitor Function in Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2024 | $162,540 | September 1, 2024 | August 31, 2025 | RODRIGUEZ, LUIS R | reporter.nih.gov |
| Dissecting Lung Spatial-Biological Niches in Early Fibrogenesis | NIH | National Heart, Lung, and Blood Institute | 2025 | $161,568 | September 1, 2025 | August 31, 2026 | GUO, JASON LIWEI | reporter.nih.gov |
| Endothelial S1PR1 promotes lung repair in post-viral ARDS | NIH | National Heart, Lung, and Blood Institute | 2024 | $161,240 | August 1, 2024 | July 31, 2025 | BRAZEE, PATRICIA LOUISE | reporter.nih.gov |
| Hypoxia-inducible factor(HIF)-driven modulation of alveolar regeneration | NIH | National Heart, Lung, and Blood Institute | 2025 | $159,624 | August 1, 2025 | July 31, 2030 | MCCALL, ABRAHAM SCOTT | reporter.nih.gov |
| Impact of mechanical stretch on the progression of pulmonary fibrosis in mouse bleomycin model | NIH | National Institute on Aging | 2024 | $158,419 | June 1, 2024 | May 31, 2026 | HUANG, YONG | reporter.nih.gov |
| Interrogation of the inflammasome to identify biomarkers of progressive interstitial lung disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $157,000 | April 1, 2021 | March 31, 2023 | OLDHAM, JUSTIN M | reporter.nih.gov |
| Sine Oculis Homeobox Homolog 1 and clusterin in Pulmonary Hypertension associated with Systemic Sclerosis | NIH | National Center for Advancing Translational Sciences | 2025 | $156,000 | June 16, 2025 | December 15, 2026 | KARMOUTY-QUINTANA, HARRY | reporter.nih.gov |
| The role of pleural mesothelium in lung injury, repair, and regeneration | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $155,324 | July 1, 2024 | July 7, 2027 | GILBERT, RACHEL | reporter.nih.gov |
| Computational Breathing Model for Robust Lung Function Assessment | NIH | National Institute of Biomedical Imaging and Bioengineering | 2025 | $150,951 | August 1, 2025 | July 31, 2027 | CASTILLO, EDWARD | reporter.nih.gov |
| Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $150,106 | January 1, 2024 | December 31, 2025 | HANNAN, RILEY T | reporter.nih.gov |
| Spatiotemporal Atlas of Cellular Networks and Ultrastructural States Mediating the Progression and Resolution of Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $146,256 | July 18, 2023 | July 17, 2026 | GUO, JASON LIWEI | reporter.nih.gov |
| Targeting fibrosis to change cancer outcomes | NIH | National Cancer Institute | 2023 to 2025 | $146,163 | August 15, 2023 | August 16, 2028 | BRECKENRIDGE, JOEY EMERY | reporter.nih.gov |
| Radiomics Features of Quantitative Interstitial Abnormalities and Early Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $141,542 | March 1, 2023 | July 31, 2024 | CHOI, BINA | reporter.nih.gov |
| Multi-omic network methods for mapping molecular trajectories of age-related lung diseases | NIH | National Heart, Lung, and Blood Institute | 2025 | $140,403 | August 1, 2025 | July 31, 2030 | SHUTTA, KATHERINE HOFF | reporter.nih.gov |
| The Role of Macrophages in Pulmonary Regeneration using a Bioengineered Whole Lung Tissue Model | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $136,674 | July 1, 2022 | June 30, 2024 | GREANEY, ALLISON MARIE | reporter.nih.gov |
| MFAP5 and Skin Scar Formation | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 to 2025 | $131,219 | May 2, 2023 | May 15, 2025 | HAN, CHEN | reporter.nih.gov |
| Investigating Histone Acetylation Modulator Function in Alveolar Regeneration and Disease Pathogenesis | NIH | National Heart, Lung, and Blood Institute | 2025 | $130,593 | August 1, 2025 | July 31, 2027 | SUN, DAWEI | reporter.nih.gov |
| Regulation and Mechanisms of Transitional Epithelial Cell Senescence in Lung Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $130,470 | January 1, 2024 | June 30, 2025 | TING, CHRISTOPHER | reporter.nih.gov |
| Hedgehog Signaling as a regulator of progenitor differentiation for organ maintenance and disease | NIH | National Heart, Lung, and Blood Institute | 2025 | $123,000 | February 1, 2025 | November 30, 2026 | YANG, XINAN HOLLY | reporter.nih.gov |
| Understanding the interstitial phenotype of impaired respiratory health through CT imaging and blood biomarkers | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $116,648 | February 1, 2022 | July 31, 2023 | LIU, GABRIELLE | reporter.nih.gov |
| Discerning the mechanism of telomere dysfunction caused by a mutant telomerase template | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $115,434 | May 1, 2021 | December 31, 2023 | HINCHIE, ANGELA MARIE | reporter.nih.gov |
| Deciphering the Regulation of TGF-b3 in Driving Myofibroblast Differentiation in Systemic Sclerosis | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2025 | $113,090 | May 15, 2025 | April 30, 2030 | HUANG, MENGQI | reporter.nih.gov |
| The role of multiciliated cell dysfunction in pathogenesis of IPF | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $109,760 | January 1, 2021 | June 30, 2023 | KIM, EUN JOO | reporter.nih.gov |
| Intracellular Osteopontin induces Pathologic Macrophage phenotypes in Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $108,512 | September 30, 2024 | September 29, 2027 | MESSERSCHMIDT, JONATHAN LEIGH | reporter.nih.gov |
| Epithelial cell mediated fibroblast activation through CTHRC1-TGFb signaling in fibrotic lung diseases | NIH | National Heart, Lung, and Blood Institute | 2025 | $107,752 | September 12, 2025 | August 31, 2027 | KHATRI, AADITYA | reporter.nih.gov |
| The role of BHLHB2 in Scleroderma-Associated Lung Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2023 to 2024 | $105,980 | July 1, 2023 | June 30, 2025 | ADEWALE, ADEGBOYEGA TIMOTHY | reporter.nih.gov |
| Targeted Death of Collagen1a1-Expressing Fibroblasts Reduces Silica-Induced Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $102,469 | September 1, 2023 | August 31, 2026 | FOSTER, DANIEL G | reporter.nih.gov |
| Adapting cell-based therapies for the treatment of pulmonary fibrosis | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $98,512 | December 1, 2023 | November 30, 2026 | WHITTY, CAROLINE | reporter.nih.gov |
| Identifying Inflammatory Signals Facilitating Ectopic Krt5+ Cell Migration and their Function in the Alveoli | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $98,512 | July 1, 2024 | June 30, 2029 | HOLCOMB, NICOLAS PHILIP | reporter.nih.gov |
| Generation of human alveolar epithelial type I cells from pluripotent stem cells | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $92,711 | June 1, 2021 | May 31, 2023 | BURGESS, CLAIRE | reporter.nih.gov |
| The role of senescence marker p16ink4a in alveolar epithelial stem cells during injury-triggered differentiation | NIH | National Heart, Lung, and Blood Institute | 2025 | $91,030 | September 30, 2025 | November 29, 2026 | LECHNER, ANDREW J | reporter.nih.gov |
| Determining the role of TP53 regulation in alveolar epithelial transitional cell state, and the contribution of alveolar epithelial transitional cell state to pulmonary fibrosis | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $90,753 | March 1, 2024 | August 31, 2026 | MOROWITZ, JEREMY | reporter.nih.gov |
| The effect of body composition on patient-centered outcomes in advanced interstitial lung disease | NIH | National Heart, Lung, and Blood Institute | 2025 | $89,860 | September 1, 2025 | August 31, 2028 | CURNOW, ANDREW | reporter.nih.gov |
| Elucidating the Role of Notch/HES Signaling in Alveolar Epithelial Type II to Type I Cell Differentiation | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $84,752 | September 24, 2024 | September 23, 2028 | LIANG, JESSICA | reporter.nih.gov |
| Corticosteroids for Acute Exacerbations of Idiopathic Pulmonary Fibrosis: Patterns and Outcomes | NIH | National Heart, Lung, and Blood Institute | 2023 | $82,928 | July 1, 2023 | June 30, 2024 | SHANKAR, DIVYA | reporter.nih.gov |
| Targeting Bcl-2 Family Proteins to Facilitate Fibroblast Apoptosis and Promote the Resolution of Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $81,798 | June 9, 2021 | June 8, 2022 | COOLEY, JOSEPH CHARLES | reporter.nih.gov |
| Investigating the role of B cells in pulmonary fibrosis resulting from STING gain-of-function autoinflammation | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $81,527 | September 4, 2020 | September 3, 2023 | GAO, KEVIN MINGJIE | reporter.nih.gov |
| Characterization of pulmonary progenitor cell dysfunction in COPA syndrome | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $77,180 | September 1, 2020 | August 31, 2023 | KOZIOL, COLIN | reporter.nih.gov |
| The Role of Macrophages in Pulmonary Regeneration using a Bioengineered Whole Lung Tissue Model | NIH | National Heart, Lung, and Blood Institute | 2024 | $76,756 | July 1, 2022 | June 30, 2025 | GREANEY, ALLISON MARIE | reporter.nih.gov |
| Metabolic regulation of fibroblast fate by ATP citrate lyase | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $76,310 | December 1, 2021 | November 30, 2023 | SMITH, SAMUEL R | reporter.nih.gov |
| Targeting the ACOD1 immunometabolic pathway of lung myeloid cells to reduce environmental exposure-induced lung disease | NIH | National Institute of Environmental Health Sciences | 2024 to 2025 | $76,018 | January 15, 2024 | December 31, 2025 | SCHWAB, AARON | reporter.nih.gov |
| The role of the epithelial-derived chemokine, CXCL12, in Idiopathic Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $75,709 | April 16, 2020 | May 15, 2022 | SULLIVAN, DANIEL | reporter.nih.gov |
| Fibrotic remodeling of lymph nodes disrupts T cell function in fibrosis and cancer | NIH | National Cancer Institute | 2021 to 2022 | $75,132 | September 1, 2021 | August 31, 2023 | BINGHAM, GRACE C | reporter.nih.gov |
| Tissue stiffness promotes pro-fibrotic metabolic dysregulation in lung fibrosis | NIH | National Heart, Lung, and Blood Institute | 2022 | $74,234 | December 1, 2020 | November 30, 2022 | THOMAS FREEBERG, MARGARET | reporter.nih.gov |
| The role of transcription factor MEOX2 in lipofibroblast function during alveolarization | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $73,258 | February 2, 2022 | November 17, 2023 | RICCETTI, MATTHEW | reporter.nih.gov |
| Targeting redox to resorb ECM | NIH | National Heart, Lung, and Blood Institute | 2022 | $67,582 | January 3, 2022 | January 2, 2023 | LINK, PATRICK | reporter.nih.gov |
| Novel Approaches for Identification of Idiopathic Pulmonary Fibrosis Therapy Targets Using Microscale Collagen Hydrogels | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $66,991 | March 2, 2020 | January 11, 2023 | CUMMINS, KATHERINE ANNE | reporter.nih.gov |
| Defining the role of the nuclear lamina in the mechanical regulation of lung fibrosis | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $56,820 | January 16, 2022 | April 30, 2023 | CARLEY, EMMA | reporter.nih.gov |
| Repurposing esomeprazole for the treatment of scleroderma | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 | $56,461 | August 17, 2022 | December 3, 2022 | GHEBRE, YOHANNES T | reporter.nih.gov |
| Influence of macrophage-fibroblast interactions and mechanotransduction on fibrotic progression | NIH | National Heart, Lung, and Blood Institute | 2022 | $55,447 | September 1, 2022 | June 30, 2023 | NOVAK, CAYMEN | reporter.nih.gov |
| The Role of Tryptophan Metabolism in Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2025 | $51,728 | September 30, 2025 | September 29, 2027 | CARTER, HANNAH | reporter.nih.gov |
| Dissecting the Role of DDR2 in the Modulation of Antibacterial Host Defense Post Fibrotic Lung Injury | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $50,809 | May 1, 2020 | August 31, 2022 | WARHEIT-NIEMI, HELEN IVORY | reporter.nih.gov |
| Thermoneutral Housing Protects from Fibrosis in IL-10 dependent manner | NIH | National Heart, Lung, and Blood Institute | 2025 | $49,538 | September 1, 2025 | August 31, 2028 | MIKHAIL, SHERIDAN | reporter.nih.gov |
| Uncovering the Roles of PIP5KDuring Cell Migration | NIH | National Heart, Lung, and Blood Institute | 2025 | $49,538 | September 15, 2025 | September 14, 2027 | DENG, YU | reporter.nih.gov |
| Engineering 3D microtissues of pulmonary fibrosis. | NIH | National Heart, Lung, and Blood Institute | 2024 | $48,974 | August 19, 2024 | August 18, 2025 | NIEVES, ELISA B | reporter.nih.gov |
| FASEB SRC: The Lung Epithelium Conference: In Health and Disease | NIH | National Heart, Lung, and Blood Institute | 2022 | $40,000 | April 1, 2022 | March 31, 2023 | KROPSKI, JONATHAN ANDREW | reporter.nih.gov |
| Lung Epithelium in Health and Disease | NIH | National Heart, Lung, and Blood Institute | 2024 | $40,000 | July 1, 2024 | June 30, 2025 | SUCRE, JENNIFER MALCOLMSRYGLEY | reporter.nih.gov |
| Aspen Lung Conference Pulmonary Fibrosis - focusing on the future | NIH | National Heart, Lung, and Blood Institute | 2024 | $30,000 | April 1, 2024 | March 31, 2025 | REDENTE, ELIZABETH FRANCES | reporter.nih.gov |
| 2025 International Workshop on Pulmonary Imaging | NIH | National Heart, Lung, and Blood Institute | 2024 | $29,805 | September 1, 2024 | August 31, 2025 | RIZI, RAHIM R | reporter.nih.gov |
| From First Breath: Lung Development, Infection, Repair and Aging | NIH | National Heart, Lung, and Blood Institute | 2023 | $16,500 | April 1, 2023 | March 31, 2024 | SHEPPARD, TERRY L. | reporter.nih.gov |
| The Lysophospholipid and Related Mediators Conference: From Bench to Clinic | NIH | National Heart, Lung, and Blood Institute | 2023 | $10,000 | April 19, 2023 | March 31, 2024 | DI LORENZO, ANNARITA | reporter.nih.gov |
| The 2024 conference on "Epithelial mesenchymal interactions in lung development and fibrosis" | NIH | National Heart, Lung, and Blood Institute | 2024 | $5,000 | October 1, 2024 | September 30, 2025 | DE LANGHE, STIJN PIET JOHAN | reporter.nih.gov |
| Targeting Matrix Stiffness in Lung Fibrosis Associated with Aging | NIH | National Heart, Lung, and Blood Institute | 2024 | $4,480 | September 1, 2018 | May 31, 2024 | ZHOU, YONG | reporter.nih.gov |
| Targeting fibrosis to change cancer outcomes | NIH | National Cancer Institute | 2023 | $1 | August 15, 2023 | August 16, 2023 | BRECKENRIDGE, JOEY EMERY | reporter.nih.gov |
| COVID-FIS: A PHASE 2 PLACEBO-CONTROLLED PILOT STUDY IN COVID-19 OF FISETIN TO ALLEVIATE DYSFUNCTION AND EXCESSIVE INFLAMMATORY RESPONSE IN OLDER ADULTS IN NURSING HOMES | NIH | National Institute on Aging | 2024 | $1 | September 15, 2020 | November 30, 2024 | PIGNOLO, ROBERT JOHN | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| Leidos Biomedical Research, Inc. | Frederick, MD | 1 | $2.96 billion | 0 | $0 |
| University of Michigan at Ann Arbor | Ann Arbor, MI | 27 | $46.2 million | 0 | $0 |
| University of California, San Francisco | San Francisco, CA | 25 | $29.8 million | 0 | $0 |
| Brigham and Women's Hospital | Boston, MA | 12 | $24.8 million | 0 | $0 |
| University of Colorado Denver | Aurora, CO | 12 | $24.4 million | 0 | $0 |
| University of Alabama at Birmingham | Birmingham, AL | 15 | $21.8 million | 0 | $0 |
| Massachusetts General Hospital | Boston, MA | 18 | $21.2 million | 0 | $0 |
| Columbia University Health Sciences | New York, NY | 7 | $18 million | 0 | $0 |
| Yale University | New Haven, CT | 14 | $17.2 million | 0 | $0 |
| Weill Medical Coll of Cornell Univ | New York, NY | 7 | $14.4 million | 0 | $0 |
| Vanderbilt University Medical Center | Nashville, TN | 13 | $14.3 million | 0 | $0 |
| Mayo Clinic Rochester | Rochester, MN | 12 | $13.9 million | 0 | $0 |
| Cedars-Sinai Medical Center | Los Angeles, CA | 7 | $13.2 million | 0 | $0 |
| University of Pittsburgh at Pittsburgh | Pittsburgh, PA | 12 | $12.3 million | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 12 | $12.2 million | 0 | $0 |
| University of Virginia | Charlottesville, VA | 10 | $9.4 million | 0 | $0 |
| Boston University Medical Campus | Boston, MA | 7 | $9.1 million | 0 | $0 |
| Northwestern University at Chicago | Chicago, IL | 6 | $8.6 million | 0 | $0 |
| University of Chicago | Chicago, IL | 6 | $8.5 million | 0 | $0 |
| University of California Los Angeles | Los Angeles, CA | 9 | $8.1 million | 0 | $0 |
| Washington University | Saint Louis, MO | 7 | $8 million | 0 | $0 |
| Ohio State University | Columbus, OH | 7 | $7.8 million | 0 | $0 |
| National Jewish Health | Denver, CO | 7 | $7.8 million | 0 | $0 |
| Baylor College of Medicine | Houston, TX | 10 | $7.7 million | 0 | $0 |
| Duke University | Durham, NC | 9 | $7.2 million | 0 | $0 |
| Translational Genomics Research Inst | Phoenix, AZ | 2 | $6.7 million | 0 | $0 |
| University of Texas HLTH Sci CTR Houston | Houston, TX | 5 | $6.4 million | 0 | $0 |
| Univ of Massachusetts Med SCH Worcester | Worcester, MA | 4 | $6.3 million | 0 | $0 |
| University of California, San Diego | La Jolla, CA | 5 | $6.2 million | 0 | $0 |
| Tulane University of Louisiana | New Orleans, LA | 7 | $5.9 million | 0 | $0 |
| University of Cincinnati | Cincinnati, OH | 4 | $5.4 million | 0 | $0 |
| University of Vermont & ST Agric College | Burlington, VT | 3 | $5.1 million | 0 | $0 |
| Cincinnati Childrens Hosp Med CTR | Cincinnati, OH | 6 | $5 million | 0 | $0 |
| University of California at Davis | Davis, CA | 4 | $3.4 million | 0 | $0 |
| Brown University | Providence, RI | 2 | $3.4 million | 0 | $0 |
| Boston Children's Hospital | Boston, MA | 2 | $3.2 million | 0 | $0 |
| University of Southern California | Los Angeles, CA | 2 | $3.2 million | 0 | $0 |
| Halo Biosciences, Inc. | Palo Alto, CA | 1 | $3 million | 0 | $0 |
| University of Illinois at Chicago | Chicago, IL | 4 | $2.9 million | 0 | $0 |
| Johns Hopkins University | Baltimore, MD | 5 | $2.9 million | 0 | $0 |
| Medical University of South Carolina | Charleston, SC | 5 | $2.8 million | 0 | $0 |
| Xemed, LLC | Durham, NH | 1 | $2.7 million | 0 | $0 |
| Virtici, LLC | Seattle, WA | 1 | $2.7 million | 0 | $0 |
| University of Florida | Gainesville, FL | 2 | $2.7 million | 0 | $0 |
| Eydis Bio, Inc. | Durham, NC | 1 | $2.6 million | 0 | $0 |
| University of Kentucky | Lexington, KY | 2 | $2.5 million | 0 | $0 |
| New York University School of Medicine | New York, NY | 1 | $2.5 million | 0 | $0 |
| North Carolina State University | Raleigh, NC | 2 | $2.4 million | 0 | $0 |
| University of Texas HLTH CTR at Tyler | Tyler, TX | 3 | $2.4 million | 0 | $0 |
| Veterans Medical Research Fdn/san Diego | San Diego, CA | 1 | $2.4 million | 0 | $0 |
| Xylyx Bio, Inc. | Brooklyn, NY | 1 | $2.4 million | 0 | $0 |
| Fibronox, L.L.C. | Tucson, AZ | 2 | $2.3 million | 0 | $0 |
| Aqualung Therapeutics Corp. | Juno Beach, FL | 2 | $2.3 million | 0 | $0 |
| SUNY Downstate Medical Center | Brooklyn, NY | 1 | $2.3 million | 0 | $0 |
| Emory University | Atlanta, GA | 1 | $2.2 million | 0 | $0 |
| University of Minnesota | Minneapolis, MN | 3 | $2.1 million | 0 | $0 |
| Univ of North Carolina Chapel Hill | Chapel Hill, NC | 1 | $2 million | 0 | $0 |
| Collagen Medical, LLC | Boston, MA | 1 | $2 million | 0 | $0 |
| Tufts Medical Center | Boston, MA | 1 | $2 million | 0 | $0 |
| Old Dominion University | Norfolk, VA | 3 | $2 million | 0 | $0 |
| Sanford Burnham Prebys Medical Discovery Institute | La Jolla, CA | 2 | $1.9 million | 0 | $0 |
| Cleveland Clinic Lerner Com-Cwru | Cleveland, OH | 2 | $1.9 million | 0 | $0 |
| University of Utah | Salt Lake City, UT | 1 | $1.7 million | 0 | $0 |
| Mdi Therapeutics, Inc. | Novi, MI | 1 | $1.7 million | 0 | $0 |
| Icahn School of Medicine at Mount Sinai | New York, NY | 1 | $1.7 million | 0 | $0 |
| Faknostics, LLC | Phoenix, AZ | 2 | $1.6 million | 0 | $0 |
| Drexel University | Philadelphia, PA | 1 | $1.6 million | 0 | $0 |
| Proteogenomics Research Instit/sys/ Med | La Jolla, CA | 1 | $1.6 million | 0 | $0 |
| University of Texas HLTH Science Center | San Antonio, TX | 1 | $1.6 million | 0 | $0 |
| SUNY at Buffalo | Amherst, NY | 1 | $1.6 million | 0 | $0 |
| University of Arizona | Tucson, AZ | 2 | $1.6 million | 0 | $0 |
| Trustees of Boston University | Boston, MA | 1 | $1.5 million | 0 | $0 |
| Oklahoma State University | Stillwater, OK | 1 | $1.5 million | 0 | $0 |
| Case Western Reserve University | Cleveland, OH | 1 | $1.5 million | 0 | $0 |
| Ut Southwestern Medical Center | Dallas, TX | 2 | $1.5 million | 0 | $0 |
| Indiana University Indianapolis | Indianapolis, IN | 1 | $1.5 million | 0 | $0 |
| Vasarya Therapeutics, Inc. | Camden, DE | 1 | $1.5 million | 0 | $0 |
| Masonic Medical Research Laboratory, INC | Utica, NY | 1 | $1.5 million | 0 | $0 |
| Rejuvenation Technologies, Inc. | Mountain View, CA | 2 | $1.4 million | 0 | $0 |
| Adiutrix Therapeutics | New York, NY | 1 | $1.4 million | 0 | $0 |
| Albert Einstein College of Medicine | Bronx, NY | 1 | $1.3 million | 0 | $0 |
| Inlighta Biosciences, LLC | Marietta, GA | 2 | $1.3 million | 0 | $0 |
| Children's Hosp of Philadelphia | Philadelphia, PA | 2 | $1.3 million | 0 | $0 |
| University of Wisconsin-Madison | Madison, WI | 2 | $1.3 million | 0 | $0 |
| Rutgers Biomedical and Health Sciences | Newark, NJ | 1 | $1.3 million | 0 | $0 |
| University of North Texas | Denton, TX | 1 | $1.2 million | 0 | $0 |
| Stanford University | Stanford, CA | 4 | $1.2 million | 0 | $0 |
| Georgia Tech Research Corporation | Atlanta, GA | 2 | $1.1 million | 0 | $0 |
| Xfibra, Inc. | Del Mar, CA | 1 | $999,601 | 0 | $0 |
| Pennsylvania State Univ Hershey Med CTR | Hershey, PA | 1 | $834,000 | 0 | $0 |
| University of Louisville | Louisville, KY | 1 | $781,145 | 0 | $0 |
| Georgia State University | Atlanta, GA | 2 | $775,226 | 0 | $0 |
| Seattle Children's Hospital | Seattle, WA | 2 | $754,404 | 0 | $0 |
| University of Iowa | Iowa City, IA | 1 | $751,734 | 0 | $0 |
| Beckman Research Institute/city of Hope | Duarte, CA | 1 | $747,000 | 0 | $0 |
| University of Kansas Medical Center | Kansas City, KS | 1 | $718,002 | 0 | $0 |
| Methodist Hospital Research Institute | Houston, TX | 1 | $705,334 | 0 | $0 |
| Novomedix, Inc. | San Diego, CA | 2 | $621,234 | 0 | $0 |
| Fibrobiologics, LLC | Charleston, SC | 2 | $605,813 | 0 | $0 |
| Altay Therapeutics, Inc. | San Carlos, CA | 2 | $599,067 | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 257 | $517,647,868 | 0 | $0 |
| 2024 | 255 | $643,339,368 | 0 | $0 |
| 2023 | 222 | $919,306,659 | 0 | $0 |
| 2022 | 219 | $718,726,346 | 0 | $0 |
| 2021 | 144 | $709,512,299 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.